CRISPR diagnostics: from trans-nuclease activity to cancer diagnosis Authors: Lei Chang, Wenjue Xu, Xiaoyan Wang, Yuanyuan Xue, Ying Zhang, Xuena Zhu, Yun Zhang, Tingbo Liang, Wenjun Liu Published: 2026 ABSTRACT The field of nucleic acid-based testing experienced a decade-long stagnation since the development of quantitative polymerase chain reaction (qPCR) in 1992 and isothermal amplification methods in the early 2000s. However, in 2016, the discovery of trans-nuclease activity in CRISPR-Cas systems revolutionized the molecular diagnostics for nucleic acids. A typical CRISPR diagnostic workflow comprises three phases: (1) target recognition through CRISPR RNA (crRNA)-guided hybridization; (2) signal transduction via trans-cleavage of engineered reporters (e.g., fluorophore-quencher oligonucleotides), and (3) signal readout using fluorescence, electrochemical, or colorimetric platforms. Emerging shortly prior to the COVID-19 pandemic, CRISPR diagnostics quickly gained prominence as a field-deployable alternative to qPCR due to its rapidity (< 1 h), minimal equipment requirements, and field adaptability. This technological paradigm underwent rigorous validation and refinement alongside the rapid evolution of SARS-CoV-2 detection, which facilitated its adaptation for cancer diagnosis. Recent advancements in sensitivity (attomolar-level detection) and specificity (single-nucleotide discrimination) have enabled transformative applications in cancer diagnostics, including: (1) identification of nucleic acid biomarkers, such as high-frequency somatic mutations, circulating nucleic acids and miRNAs; and (2) detection of non-nucleic acid biomarkers, including epigenetic aberrations, proteins, small molecules and metabolite biomarkers. This review chronicles the decadal evolution of CRISPR diagnostics, with particular emphasis on recent advancements of its application in cancer diagnosis. We critically evaluate persistent technical limitations, including PAM sequence restriction, suboptimal sensitivity and specificity, quantitative constraints, and unmet point-of-care testing (POCT) in complex biological matrices. Additionally, we discuss prospective solutions to address these challenges. Introduction CRISPR-Cas systems, originally discovered as adaptive immune mechanisms in prokaryotes, have revolutionized molecular diagnostics by offering programmable, precise, and rapid nucleic acid detection [1, 2]. These systems leverage the sequence-specific recognition mediated by guide RNAs (crRNAs) and the trans-nuclease activity of Cas enzymes to convert target recognition into amplified signals. Over the past decade, CRISPR diagnostics have advanced from foundational discoveries into versatile platforms with transformative potential in infectious disease management, cancer diagnostics, and point-of-care testing (POCT) [3]. This progression has been driven by innovations in enzyme engineering, assay design, and integration with amplification technologies, positioning CRISPR as a compelling alternative to conventional methods such as qPCR and sequencing. CRISPR-Cas systems are broadly categorized into two classes: Class I, characterized by multi-subunit effectors (e.g., Cascade-Cas3 complex), and Class II, comprising single-protein effectors (e.g., Cas9, Cas12, Cas13) [4]. Owing to their simplicity and adaptability, Class II systems have become especially prominent in diagnostic applications. In particular, Type V CRISPR-Cas12a and Type VI CRISPR-Cas13a exhibit remarkable trans-nuclease activity, indiscriminately degrading single-stranded DNA (ssDNA) or RNA (ssRNA) upon target recognition [5, 6]. Structurally, Cas12a’s bilobed architecture undergoes significant conformational changes upon crRNA–target DNA hybridization, activating its RuvC domain for collateral cleavage [7]. Likewise, Cas13a’s HEPN domains form a catalytic site upon RNA target binding, enabling non-specific RNA degradation [8]. These characteristics form the basis of diagnostic platforms such as DETECTR (DNA Endonuclease-Targeted CRISPR Trans Reporter) and SHERLOCK (specific high-sensitivity enzymatic reporter unlocking), which can achieve attomolar sensitivity when integrated with isothermal amplification techniques such as recombinase polymerase amplification (RPA) or loop-mediated isothermal amplification (LAMP) [5, 9]. The COVID-19 pandemic notably accelerated advancements in CRISPR-based diagnostics, exemplified by the SHERLOCK assay, which received FDA emergency use authorization in 2020. Further innovations, including one-pot assays and multiplexed microfluidic platforms, have streamlined workflows to yield results within 15–40 min [10, 11]. These developments have demonstrated significant clinical utility, particularly in resource-limited settings, underscoring the adaptability of CRISPR diagnostics in addressing global health crises. Beyond infectious diseases, CRISPR diagnostics have transformed cancer detection by enabling highly sensitive and specific analyses of both nucleic acid and non-nucleic acid biomarkers. For nucleic acid detection, systems based on Cas12a, Cas13a, and Cas9 target oncogenic mutations (e.g., EGFR T790M, KRAS G12D, BRAF V600E) and tumor suppressor gene aberrations (e.g., TP53, BRCA1) using innovative methods such as recombinase polymerase amplification (RPA), blocker displacement amplification (BDA), and self-sustaining circuits (e.g., CONAN), achieving variant allele frequencies (VAFs) as low as 0.0001% [12–14]. Liquid biopsy applications leverage CRISPR diagnostics platforms such as SHERLOCK and HiCASE to detect circulating tumor DNA (ctDNA) and extracellular vesicle (EV)-derived RNA, thus facilitating non-invasive early diagnosis and minimal residual disease monitoring [15, 16]. For microRNA (miRNA) detection, approaches integrating Cas12a/Cas13a with rolling circle amplification (RCA), split CRISPR systems, and electrochemical biosensors have achieved attomolar sensitivity for biomarkers like miR-21 and miR-141 [17–19]. In addition to nucleic acid biomarkers, CRISPR technology has also been applied to epigenetic, proteomic, and metabolic biosensing. Epigenetic aberrations, such as methylated SEPT9 gene, are identified through bisulfite conversion or methylation-sensitive restriction enzymes (MSREs) digestion in combination with CRISPR-Cas12a, while nanopore sequencing platforms (e.g., STRique) enable single-molecule methylation profiling [20]. Protein biomarkers (e.g., IL-6, VEGF) are detected using CRISPR-linked immunosorbent assays (CLISA) or aptamer-CRISPR hybrids, thereby offering greater sensitivity than conventional ELISA [21]. Furthermore, small molecules (e.g., ATP, NAD+) and metabolites are quantified through DNAzyme-CRISPR cascades, aptamer-based systems, and allosteric transcription factors (aTFs) that transduce ligand binding into CRISPR-activatable signals [22–24]. Collectively, these innovations in CRISPR diagnostics have bridged molecular precision with clinical scalability, advancing cancer diagnostics across diverse biomarker classes. Despite these advancements, several challenges remain. The CRISPR-Cas system’s dependence on protospacer adjacent motifs (PAMs) or protospacer flanking sequences (PFS) limits targetable regions [25]. In the absence of nucleic acid amplification, CRISPR-Cas systems can only detect analytes at the picomolar level, generally insufficient for clinical applications [3]. Although single-nucleotide discrimination has been achieved in reported CRISPR-Cas assessments, mismatches located outside the crRNA seeding region may still be tolerated [26, 27]. Furthermore, most CRISPR-based diagnostic assays provide only qualitative “yes/no” outputs rather than quantitative data. Finally, many CRISPR diagnostic platforms also require laboratory-grade equipment for signal detection, which impedes their deployment in resource-limited or point-of-care settings. The next generation of CRISPR-based diagnostics aims to overcome these limitations by achieving “PAM-free”, ultra-sensitive, ultra-specific, quantitative assays and POCT. Advances in Cas enzyme engineering, crRNA optimization, and machine learning–guided design hold promise for enhanced performance. Meanwhile, collaborative efforts spanning molecular biology, nanotechnology, and microfluidics will drive the translation of CRISPR-based platforms into robust and scalable diagnostic tools. Structural and biochemical basis of CRISPR diagnostics CRISPR-based diagnostics predominantly exploit the target-activated trans-nuclease activity of CRISPR effector proteins (e.g., Cas12, Cas13, and Cas9). This process can be mechanistically divided into three coordinated phases: (i) target search (Fig. 1a), (ii) target binding (Fig. 1b), and (iii) trans-nuclease activation (Fig. 1c). Fig. 1Structural and biochemical basis of CRISPR diagnostics. a Target search. For PAM-dependent effectors such as Cas9 or Cas12a, a target search mechanism combining three-dimensional diffusion and one-dimensional sliding is employed to locate specific DNA targets. In contrast, Cas13a, which does not require a PAM or PFS, searches for RNA targets directionally from the 3′ end to the 5′ end. b Target binding. Upon target localization, complementary base pairing proceeds from the proximal regions adjacent to the PAM or PFS toward the distal regions. If mismatches occur within the seed region or mismatch-sensitive region, full complementarity or proper R-loop formation is disrupted, thereby preventing the effector from reaching an active state. c Trans-nuclease activation. Successful full matching or R-loop formation induces conformational changes in the catalytic domains, enabling Mg2+-dependent cleavage of substrate nucleic acids in trans. Structural and biochemical basis of CRISPR diagnostics. a Target search. For PAM-dependent effectors such as Cas9 or Cas12a, a target search mechanism combining three-dimensional diffusion and one-dimensional sliding is employed to locate specific DNA targets. In contrast, Cas13a, which does not require a PAM or PFS, searches for RNA targets directionally from the 3′ end to the 5′ end. b Target binding. Upon target localization, complementary base pairing proceeds from the proximal regions adjacent to the PAM or PFS toward the distal regions. If mismatches occur within the seed region or mismatch-sensitive region, full complementarity or proper R-loop formation is disrupted, thereby preventing the effector from reaching an active state. c Trans-nuclease activation. Successful full matching or R-loop formation induces conformational changes in the catalytic domains, enabling Mg2+-dependent cleavage of substrate nucleic acids in trans. Target search: PAM/PFS interrogation and facilitated diffusion The initial phase involves the kinetic interrogation of target nucleic acids by ribonucleoprotein (RNP) complexes composed of a Cas effector and its associated guide RNA. For DNA-targeting systems such as Cas9 and Cas12, target search critically depends on recognition of the protospacer adjacent motif (PAM) [5, 28]. A specialized PAM-interacting (PI) domain scans double-stranded DNA via a combination of three-dimensional diffusion and transient one-dimensional sliding [29–32], thereby rapidly sampling potential PAM sites. This PAM-first mechanism substantially reduces the search space, as only PAM-containing loci are subjected to sequence interrogation. The energetic contribution of PAM binding stabilizes the initial interaction and promotes local DNA unwinding. Upon PAM recognition, Cas proteins induce localized duplex destabilization, exposing the protospacer region to enable RNA–DNA hybridization. This step often constitutes a major kinetic barrier in many systems [33]. In contrast, although Cas13a does not require a protospacer flanking sequence (PFS), some Cas13 orthologs exhibit preferences for specific PFS elements that can modulate targeting efficiency. However, these constraints are generally weaker and less universal than canonical PAM requirements [34]. At the molecular level, the search process is governed by a balance of electrostatic interactions, conformational flexibility, and sequence-dependent energy landscapes, ensuring rapid yet selective target identification. Target binding: structural rearrangement and specificity checkpoint Following PAM or PFS recognition, the CRISPR complex transitions from a search mode to a binding-competent state, initiating R-loop formation. The R-loop is a three-stranded nucleic acid structure consisting of an RNA–DNA (or RNA–RNA) hybrid between the crRNA spacer and the target strand, along with a displaced non-target DNA strand in DNA-targeting systems. R-loop formation typically initiates at the seed region proximal to the PAM, where base pairing is most stringent, and subsequently propagates along the protospacer to form a stable intermediate. In the case of Cas12, approximately 20 nucleotides of complementarity are sufficient to stabilize the R-loop structure [35]. This process is accompanied by extensive conformational rearrangements within the Cas protein. In Cas9, for instance, activation is allosterically coupled to directional R-loop formation, a process that can be delineated into four distinct phases. (i) Initial recognition: PAM binding induces local DNA melting and stepwise guide–target hybridization, initiated from a bipartite seed sequence comprising nucleotides 1–5 and 6–10. (ii) Domain rearrangements: Early extension of the R-loop displaces the REC2 and REC3 domains, thereby opening the central binding channel and stabilizing the PAM-distal DNA duplex. (iii) Checkpoint state: Upon formation of a 12–16 bp heteroduplex, the HNH nuclease domain undocks from the RuvC/PI interface and adopts a catalytically incompetent “checkpoint” conformation. (iv) Activation: Completion of the R-loop (> 17 bp) triggers a ~ 140° rotation of the HNH domain toward the target strand cleavage site, accompanied by REC2 displacement and distortion of the guide–target heteroduplex. This conformational rearrangement exposes the RuvC active site and enables Mg2⁺-dependent cleavage of both DNA strands [36, 37]. In Cas12, the conformational changes underlying activation can be divided into five phases. (i) Seed formation: A 5 bp RNA–DNA heteroduplex is stabilized by the REC1 domain and a RuvC loop, enabling initial melting of the PAM-distal DNA. (ii) Delayed contacts: During extension to approximately 10–15 bp, the REC2 domain remains flexible and the bridge helix is disordered, which prevents premature nuclease activation and ensures R-loop reversibility, thereby promoting high specificity. (iii) Checkpoint and RuvC exposure: Only after forming a 16–20 bp heteroduplex does REC2 dock onto the RNA–DNA duplex, anchoring the bridge helix. This docking triggers the RuvC lid to transition from a disordered loop into an α-helix, exposing the active site and positioning the non-target strand (NTS) for cleavage. (iv) NTS cleavage: The NTS is secured in the RuvC active site through a conserved phenylalanine (F999) base-stacking interaction and two Mg2+ ions. (v) Target strand cleavage and resetting: Following NTS cleavage, REC2 dissociates and the RuvC lid reverts to an inactive loop. The Nuc domain swings outward, bending the target strand into the RuvC active site for the second cleavage event. The lid must be re-activated, creating a kinetic barrier that enhances fidelity [35, 38], whereas in Cas13a, research has demonstrated that nuclease activation is decoupled from target RNA binding, with an allosteric switch region ensuring that only correctly paired RNAs trigger HEPN-mediated cleavage. Specifically, the guide RNA contains two functionally distinct regions: a central seed region (guide nucleotides 9–14) that is critical for stable activator RNA binding, and a separate “HEPN nuclease switch” region (guide nucleotides 5–8) that gates catalytic activation. Mismatches within the switch region (positions 5–8) can paradoxically increase binding affinity while completely abolishing HEPN nuclease activation, indicating that tight RNA binding does not necessarily lead to catalysis. Structural data (PDB: 5XWP) reveal that base pairing in the switch region positions the phosphate backbone of the activator RNA, enabling residues such as S786 (in the HEPN-1 domain) and K558 (in the helical-II domain) to sense the geometry of the RNA duplex. This sensing triggers a conformational rearrangement that brings the two HEPN domains together to form a composite, catalytically competent active site. Mismatches in the switch region trap Cas13a in a non-catalytic yet tightly bound state, thereby acting as a late checkpoint that prevents indiscriminate cleavage [39] (Table 1). Table 1A summary of reported CRISPR diagnostics for cancer biomarkers detectionSignature of cancer biomarkerTargetPre-amplificationCRISPR-Cas systemReaction optimizationReporter and readoutOne tube/one stepDetection time costQuantitativeLODVerification in biological samplesClinical samplesSensitivity and specificityReferencesMutationEGFR T790MPre-concentrated by rotary evaporationAsCas12aNodsDNA reporter; fluorescent and electro-chemical readoutNo1.5 h sample preparation + 3 h CRISPR-Cas reaction + 2 min readoutNo10aM and 0.1% VAFsCommercial cell-free DNA reference standard in human plasmaNoNA[94]EGFR L858RRecombinase Polymerase Amplification (RPA)LbCas12aNossDNA-FQ reporter; fluorescent readoutYes1 h at 42˚CYes, commercial digital chip0.3 copies/μL (0.498 aM)Mock multiplex cfDNA samplesNoNA[12]EGFR L858RPCRLbCas12a10% glycerol, enhance temperature to 48˚CssDNA-FQ reporter; fluorescent readoutNoNANo0.001% VAFsSimulated sample with MT plasmid varying from 10 fM to 100 pM spiked in 1 nM WT to simulate VAF of 0.001–10%NoNA[13]EGFR T790MImproved allele-specific polymerase chain reaction (iARMS-PCR) & single base extensionLbCas12aNossDNA-FQ reporter; fluorescent readoutNoNANo0.002% VAFsHuman genomic DNA extracted from 500 μL of blood (n = 2)YesNA[96]EGFR L858RMscI restriction enzyme with the recombinase-aided isothermal amplification (RAA) technique (MRE-RAALbCas12aNossDNA-FQ reporter; fluorescent readoutMicrofluidic chip1 hNo0.001% VAFsClinical samples(n = 10, 6 positive and 4 negative)YesNA[97]EGFR (exon19 deletion)PCRLbCas12aNossDNA-FQ reporter; fluorescent readoutNo36 minNoNALung adenocarcinoma tumor extracted DNA(n = 18)Yes99.6% accuracy(0.4% false-negative rate))[98]NPM1 gene c.863_864 4-bp insertions, KIT gene p.W557_K558del, BRAF p.V487_T491del, EGFR p.E746_A750delERA isothermal amplificationengineered AsCas12a protein variantNossDNA-FQ reporter; fluorescent readoutYes30 minNo0.01% VAFsGenomic DNA extracted from the blood cell sample of AML patients(n = 108)YesIdentifies NPM1 mutations in 30 out of 108 AML patients[99]EGFR L858RRPACas12f1NossDNA-FQ reporter; fluorescent readoutNo15-20 min RPA + 30-60 min CRISPR-Cas reactionNo10 copies per microliter (16.8 aM)Formalin-fixed paraffin-embedded (FFPE) NSCLC tumor specimens(n = 22, 12 positive and 10 negative)Yes100% and 100%[100]EGFR E746-A750 mutationLigation-initiated loop-mediated isothermal amplification (LAMP)LbCas12aNoMB-ssDNA monolayer was successfully modified on the surface of the GCE/GDY-AuTNP selectrode,Electro-chemical reporter and readoutNo22-min LAMP + 30-min CRISPR-Cas12a reactionNo17 fMStandard sampleNoNA[101]EGFR L858R, KRAS G12D, and EGFR T790MNAspCas9NANGSNANANANA20 ng reference samplesNo1[102]KRAS G12VCRISPR Cas9 mediated selective RPACas9NASanger sequencingNA20-min incubation timeNANA60 ng genomic DNAYes100% in sample with MAF = 0.1%, 1%, and 5%(n = 3); 70% of the samples with MAF = 0.01%(n = 10)[103]KRAS-G12DRPACRISPR-Cas9 reaction following RCA amplificationNoBiotin probe, HRP-gold nanoparticles complex (hGNPs), colorimetric assayNANANA0.2 fM and 0.01% VAFsSpiked the genome DNA (extracted from the cells stably expressed KRAS-G12D-EGFP) into fetal bovine serum (FBS, 100% and 50%),NoNA[104]EGFR-ΔE746–750, EGFR-L858R, EGFR-T790M and KRAS-G12CRPA/PCRLbCas12aNossDNA-FQ reporter; fluorescent readoutNo50 minNo10 aM and 0.02% VAFsPlasma DNA of NSCLC patients(n = 30)Yes100% and 100%[105]KRAS G12DAsymmetric PCRLbCas12aNossDNA-FQ reporter with a perfect match for WT target and a mismatch for MT target; fluorescent readoutNoNANo0.0001% VAFsHuman genomic DNA extracted from pancreatic cancer samples(n = 15)Yes100% and 100%[106]KRAS G12D, BRAF V600E, EGFRvIII deletion, IDH1R132HNoLwaCas13aself-cascade amplificationRNA–DNA hybrid reporter comprising (1) a fluorescent RNA segment cleavable by Cas13a/crRNA, (2) a fluorescent quencher and (3) a DNA template for target RNA transcription by T7 polymerase; fluorescent readoutYes40 minNoSub-attomolar level, 0.01% VAFsSerum exosome mRNA from different cancer patients(15 non-cancer patients, 107 CRC patients, 60 glioma patients;)Yes100% and 100%[107]PIK3CA 1633G > ANoLbCas12aSelf-cascade amplificationSwitchable-caged guide RNA (scgRNA); Fluorescent readoutYes30 minNo10 aM and 0.1% VAFsGenomic DNA extracted from bladder cancer tissue(n = 6)Yes100% and 100%[14]PIK3CA H1047RRCALbCas12aNossDNA-FQ reporter; fluorescent readoutNo1.5 hNo10 aM and 0.036% VAFsMutant targets of the PIK3CA H1047R (10 fM,100 fM, and 1 pM) were spiked in 5% normal human serumNoNA[108]PTEN R130Q, BRAF V600E, and TP53 R248WSpecific PCRLbCas12aNossDNA-FQ reporter; fluorescent readoutNoNANo0.1% VAFsDNA samples from PCOS and ovarian cancer patient(n = 6)Yes100% and 100%[109]BRAF V600EBlocker Displacement amplification(BDA)Un1Cas12f(Cas14a)Following T7 exonuclease cleavagessDNA-FQ reporter; fluorescent readoutNoNANo0.1% VAFsGenomic DNA extracted from human colorectal carcinoma cellsNoNA[110]IDH1-R132HRPAFnCas12aNossDNA-FQ reporter; fluorescent readoutNo1 hNoNAGlioma tissue samples. 58 previous frozen tissue and 46 recent fresh tissue samples of adult diffuse gliomaYes91.4%, 95.7%in the frozen sample group;96.1%, 89.7% in the fresh sample group[112]Fusion genesNACas9NANanosequencingNANANANA6 tumor samplesYesNA[115]PML/RARA fusion geneRCAFnCas12aFollowed by intermolecular G- quadruplex confinementssDNA-FQ reporter; fluorescent readoutNoNANo0.86 fMFusion gene concentration spiked in 1% human serumNoNA[116] BCR::ABL1 PCRCas13aNAssRNA-FQ reporter; fluorescent readoutNoNANoNARNA was extracted from 10 million cells in total with the number of HL-60 cellsNoNA[117] BCR::ABL1 RT-RPALwaCas13aFollowing T7 transcriptionssRNA-FQ reporter; fluorescent readoutYes1 hNo10 fMRNA was extracted from dried blood spot of CML patients(n = 44)Yes100% and 100%[118]TP53 p.R273 mutantPCRLbCas12aNossDNA-FQ reporter; fluorescent readout, lateral flow assayNoNANoNAMock cfDNA samples derived from cell cultureNoNA[113]BRCA1 3232A > GRPAAaCas12bNossDNA-FQ reporter; fluorescent readoutNoNANo1aM and 1% VAFsDNA oligos commercially purchasedNoNA[50]cryptic mutations in BRCA1NACas9NASequenced these regions with long reads (> 10 000 bp)NANANANAFreshly grown lymphoblasts were loaded onto a high molecular weight library system (Sage Science, Beverly, Massachusetts, USA) and lysed directly in agarose gelsNoNA[114]FLT3 D835YRestriction enzyme-integrated RPACas12aNAssDNA-FQ reporter; fluorescent readoutNo40 minNo0.001% VAFs80 AML patient blood samplesNo100% and 100%[122]MYD88L265PNodeactivated Cas9 (dCas9)NAOrous anodised aluminium (PAA)-based sensing chip, electrical detectionNo40 minNA1.37 nMBlood/cell/tissue genomic DNA extraction from 13 DLBCL patientsYesNA[123]Melanocortin l receptor (MC1R) T305C, T363C, and G727APCRenAsCas12a40 mM Mg2+ssDNA-FQ reporter; fluorescent readoutNoNANoNASynthesized target geneNoNA[124]GNAQ Q209PAllele-specific PCRAsCas12aNAssDNA-FQ reporter; fluorescent readoutNoNANo10 ctDNA-like copies/mL of human plasmaPlasma samples from metastatic UM patients(n = 4)YesNA[125]Circulating tumor DNAEGFR L858R and BRAF V600ERPALwaCas13aT7 in vitro-transcriptionssRNA-FQ reporter; fluorescent readoutNo > 2 hNo1 aM and 0.1% VAFsMock cfDNA samples with allelic fractions as low as 0.1%NoNA[9]EGFR L858R, EGFR T790M, EGFR exon 19 deletionRPALwaCas13aT7 in vitro-transcriptionssRNA-FQ reporter; Lateral flow readout fluorescent readoutNo30 min-3 hYes2aMPatient-derived cfDNA samplesYesNA[15]EGFR T790M/C797SPCRCas13aNossRNA-FQ reporter; fluorescent readoutNoNANo1% VAFcfDNA extracted from NSCLC plasma samples(n = 140)Yes88.1%&100%[16]Breast cancer gene-1 (BRCA-1)NoCas12aNoA 20 nm sized Au nanoparticle (20-AuNP) and 60 nm sized Au nanoparticle (60-AuNP) connected by a FITC-modified double-strand DNA (dsDNA) and single-strand DNA (ssDNA)No30 minNo0.34 fMcfDNA extracted from cell culture mediaNoNA[122]ctDNA KRASExponentialamplification reaction(EXPAR)LbCas12aNoSignal unit (ssDNA-MB@Fc/ UiO-66-NH2) consisting of methylene blue-modified ssDNA as the biogate to encapsulate ferrocene signal molecules within UiO-66-NH2 nanocarriersNoNANo0.11 fMSimulated cfDNA sample by adding different levels of ctDNA to human serum samples diluted 20 timesNoNA[123]Breast cancer gene-1 (BRCA-1)NoCas12aNoSingle nanoparticle dark-field microscopy (DFM) imagingNo40 minNo0.081 fMSynthetic DNANoNA[124]EGFR (exon 19 deletion, T790M, L858R)Nodeactivated Cas9 (dCas9)NoAllele specific qPCRNANANA0.1% allele frequency18 NSCLC patient-derived cfDNA samplesYes8 out of 13[64]PIK3CA exon 9 mutationNodCas9-sgRNA covalently immobilized on graphene oxide screen printed electrodesNAElectrochemical impedance spectroscopy (EIS) analysisNALinear detection limits between 2 and 20 nM for 120 bp ctDNA’s in 40 sNALinear detection limits between 2 and 20 nM for 120 bp ctDNA’s in 40 sSynthetic ctDNANoNA[125]EGFR L858RNodRNP (dCas9-sgRNA) immobilized on carboxyl microspheresNAElectrochemical readoutNANANA2.86 fM and 0.001%VAFctDNA (EGFR L858R) extracted from plasma samples in NSCLC patients (n = 10)YesAUC = 0.990[126]miRNAmiR-21, miR-196a, miR-451a and miR-1246Rolling-circle amplificationCas12aNoSmartphone-based fluorescence detection and with the lateral-flow format for visual readoutsYes20 min to 3 hNoSingle-digit femtomolarEvs’ RNA isolated from the plasma samples of four control donors and four patients with PDACYesSingle-marker detection yielded modest area under the curve (AUC) values ranging from 0.677 (95% confidence interval (CI), 0.486–0.868) for miR-196a to 0.793 (95% CI, 0.635–0.951) for miR-451a. The EV-Sig panel combining miR-21, miR-451a and miR-1246 greatly improves the diagnostic power to an AUC of 0.853 (95% CI, 0.726–0.979)[17]miR-21NoCas12a(split Cas12a system (SCas12a), consisting of a Cas12a enzyme and a split crRNA)NossDNA-FQ reporter; fluorescent readout, lateral flow assayNo20 min reaction timeNo100 fMPlasma samples obtained from seven individuals (aged 25 to 60 years) diagnosed with cervical cancer and three healthy individuals (aged 25 to 60 years)Yes100% and 100%[18]miR-21,miR-92aExponentialamplification reaction(EXPAR)Cas12j variantsNossRNA-FQ reporter; fluorescent readoutNo10 min reaction timeNo1 fMPlasma samples from lung cancer patients (n = 20) and healthy controls (n = 20)Yes90% sensitivity and 95% specificity for miR-21, and 80% sensitivity and 95% specificity for miR-92a[127]miR-200a and miR-126Dumbbell probe initiated multi-Rolling Circle AmplificationLbCas12aNossRNA-FQ reporter; fluorescent readoutNo30 minNo5.44 pMLung cancer/adjacent/normal tissue specimensYesAUC for miR-200a and miR-126 indistinguishing cancer tissue from adjacent tissue was 0.8800 and 0.8700, while in identifying cancer tissue from normal tissue was 0.8850 and 0.9100, respectively; the combined index of miR-200a and miR-126 exhibited AUC = 0.9300) and cancer vs normal tissue (AUC = 0.9400)[128]miRNA-10bNoLbCas12aNossDNA-FQ reporter; lateral flow assay, fluorescent readoutNoNANo5.53 fMSerum samples from glioma patientsYesNA[129]miRNA-21Ligation-recognition triggered Recombinase Polymerase Amplification (RPA)Cas12aNoFunctional Mango RNA aptamer/TO1-Biotin complexes serve as modular signal catalysts of reportersYes40 minNo3.43 aMPlasma and cell samples derived from patients with breast cancerYesNA[13]miRNA-141NACas12a3D DNA Walker mediated CRISPR/Cas12a cascade signal amplificationElectrochemical readoutNo150 min for hybridization and 30 min for reactionNo0.14 fMDifferent concentrations of the miRNA-141 were added into human serumNoNA[19]miR-122b, miR-21, and let-7aStemloop mediated reverse transcription and RPALbCas12a complexed with short crRNA-18 which contains 18-bp complementary regionNossDNA-FQ reporter; fluorescent readoutNo30 min for reactionNo7.8 aM8 blood samples from cancer patientsYesNA[131]miR-21-5pNoLwaCas13aCRISPR/Cas13a sensing components are encapsulated in liposomes and delivered them into EVs through liposome-EV fusionssRNA-FQ reporter; fluorescent readoutNo30 min for incubationYes, gold microdisk arraysNAPlasma samples from ovarian/mullerian cancer patients (n = 5) and normal healthy controls (n = 3,YesNA[132]miR-21,sub-circHIPK3NoCas13aNossRNA-FQ reporter; fluorescent readoutNoNAYes, polydisperse droplet digital10 aMClinical samples from CRC patients and healthy peopleYesNA[133]miR-21NoCas12a and Cas13aThe surface protein of EVs was detected by Cas12a using antibody-DNA conjugates to transfer the signal of the protein to DNA, while the inner miRNA was analyzed by Cas13a through EV-liposome fusionRNA reporters (green fluorescence),DNA reporters (red fluorescence); fluorescent readoutNo30 min for reactionYes, microfluidic chip containing 188,000 microwells214 EVs/μL31 blood samples, 21 from breast cancer patients and 10 from healthy donorsYesThe specificity and sensitivity for PD-L1 alone were 90 and 57%,respectively,while for miR-21 alone,the specificity and sensitivity were 50and 95%. The concurrent assessment of dual markers PD-L1 and miR-21 on single EVs achieved a specificity of 100%and a sensitivity of 81%[134]Epigenetic aberrationsMethylated SEPT9 (mSEPT9)MSRE treated, RPACas12aNossDNA-FQ reporter; fluorescent readoutNo15 min for reactionNo1 copy/μL and 0.01% methylated SEPT9 can be clearly distinguished from a mixture of excess background gDNAFifty-three cases of exfoliated cervical cells(CEC) samples from 27 patients with cervical cancer and 26 patients with non-cervical cancer were collectedYes100% and 92.3%[138]Methylated SEPT9 (mSEPT9)Multiplex PCR reactionLbCas12aNoOligonucleotide-nanoparticle reporter (Oligo-Nano reporter), fluorescent readoutNo40–60 minNo100 fM and 0.1%Consisting of four tissue DNA samples from CRC patients and 16 healthy human buffy coat DNA samplesYesNA[139]CpG methylationNoCas12aNoNanopore sequencingNANANANAHigh-molecular-weight (HMW) DNA extracted from undifferentiated hiPSCs of patientsYesNA[20]DNA adenine methylation methyltransferase (Dam MTase) activityNoCas12a( TdT-IU-CRISPR/Cpf 1(poly-T tail produced and prolonged in the presence of TdT and dTTP, recognition region of crRNA was designed to contain a 23 bp poly-A sequence.)NossDNA-FQ reporter; fluorescent readoutNo120 min for reactionNo1.26 × 10–3 U/mLDifferent concentrations of Dam MTase (0.003, 0.01 and 0.03 U/mL) were spiked in 10% normal human serumNoNA[140]DNA adenine methylation methyltransferase (Dam MTase) activityDNA Mtase and restriction endonuclease triggered strand displacement amplificationCas12aNossDNA-FQ reporter; fluorescent readoutNoThe reaction times of methylation and GlaI cleavage, SDA, and the trans-cleavage of CRISPR/Cas12a were 40, 80, and 50 min, respectivelyNo2.458 × 10–3 U/mLDifferent concentrations of Dam MTase ( 0.1, 0.5 and 1.0 U/mL) were spiked in 10% normal human serumNoNA[141]Protein biomarkersIL-6 and VEGFT7 RNA polymerase transcriptionCas13aCRISPR/Cas13a signal amplification linked immunosorbent assayssRNA-FQ reporter; fluorescent readoutNoNANo45.81 fg/mL (2.29 fM) for IL-6 and 32.27 fg/mL (0.81 fM) for VEGFAdded human IL-6 to 20% and 100% mouse serumNoNA[21]AFPNoLbCas12aNoMB-invertase; glucose readoutNo1 h incubationNo0.01 μg/mLTen-fold serial dilution of AFP biomarker ranging from 100 μg/mL to 0.01 μg/mL in a 5% human serum solutionNoNA[142]PSACatalyzed hairpin assembly (CHA)Cas12aNoUCNPs-ssDNA-Q, colorimetric readout by ultraviolet detectionNo1 h reactionNo0.01 ng/mLHuman serumNoNA[143]AFPNo, aptamer bindingCas12aNoblack hole quencher-2 (BHQ-2) labeled extremely short reporter (5 nt) is linked onto QDs@ASM, fluorescence readoutNoNANo4.12 pg/mL35 cases of appropriately-diluted human serum samples (venous blood source, Fig. 4A) collected from 25 cases of liver cancer patients [LCPs, diagnosed with abnormal AFP contents (> 9 ng/mL)]YesNA[144]Protease (e.g. Ulp1)NoCas13aMulti-component controlled activation system of Cas13 by N-terminus taggingssRNA-FQ reporter; fluorescent readoutNoNANo48.8 pg/μLCell lysatesNoNA[145]telomerase activityDroplet digital hyperbranched amplificationCas12aNossDNA-FQ reporter; fluorescent readoutNoNANo6.3 cells/ μ LBreast cancer cell lysatesNoNA[146]Small molecule and metabolite biomarkersNAD+, ATPNAD+, ATP activated DNA ligationCas12aNossDNA-FQ reporter; fluorescent readoutNoNANo10 pM for NAD and 50 pM for ATPHeLa cell lysatesNoNA[148]ATPAptamer or DNAzyme incubationCas12aNossDNA-FQ reporter; fluorescent readoutNoNANo87 pMCell lysatesNoNA[149]ATPAptamer incubationCas12aNochemiluminescenceNoNANo84.3 nMDifferent concentrations of ATP were incubated with 10% normal human serum to prepare spiked samplesNoNA[150]ATPAptamer incubation, RCACas12aNossDNA-FQ reporter; fluorescent readoutNo1-2 hNoLinear increase of fluorescence signals in the range of 10–250 μmBlood samples from wildtype and transgenic AD miceNoNA[22]ATPAptamer incubationCas12aNossDNA-FQ reporter; fluorescent readoutNo1 h reactionNo0.47 uMCell lysatesNoNA[23]uric acid and p-hydroxybenzoic acidaTFs bindingCas12aNossDNA-FQ reporter; fluorescent readoutNo5–10 min to get fluorescence if uric acid, in the sample is higher than 250 nMNo10 nMClinical serum samplesYesNA[24] Table 1A summary of reported CRISPR diagnostics for cancer biomarkers detectionSignature of cancer biomarkerTargetPre-amplificationCRISPR-Cas systemReaction optimizationReporter and readoutOne tube/one stepDetection time costQuantitativeLODVerification in biological samplesClinical samplesSensitivity and specificityReferencesMutationEGFR T790MPre-concentrated by rotary evaporationAsCas12aNodsDNA reporter; fluorescent and electro-chemical readoutNo1.5 h sample preparation + 3 h CRISPR-Cas reaction + 2 min readoutNo10aM and 0.1% VAFsCommercial cell-free DNA reference standard in human plasmaNoNA[94]EGFR L858RRecombinase Polymerase Amplification (RPA)LbCas12aNossDNA-FQ reporter; fluorescent readoutYes1 h at 42˚CYes, commercial digital chip0.3 copies/μL (0.498 aM)Mock multiplex cfDNA samplesNoNA[12]EGFR L858RPCRLbCas12a10% glycerol, enhance temperature to 48˚CssDNA-FQ reporter; fluorescent readoutNoNANo0.001% VAFsSimulated sample with MT plasmid varying from 10 fM to 100 pM spiked in 1 nM WT to simulate VAF of 0.001–10%NoNA[13]EGFR T790MImproved allele-specific polymerase chain reaction (iARMS-PCR) & single base extensionLbCas12aNossDNA-FQ reporter; fluorescent readoutNoNANo0.002% VAFsHuman genomic DNA extracted from 500 μL of blood (n = 2)YesNA[96]EGFR L858RMscI restriction enzyme with the recombinase-aided isothermal amplification (RAA) technique (MRE-RAALbCas12aNossDNA-FQ reporter; fluorescent readoutMicrofluidic chip1 hNo0.001% VAFsClinical samples(n = 10, 6 positive and 4 negative)YesNA[97]EGFR (exon19 deletion)PCRLbCas12aNossDNA-FQ reporter; fluorescent readoutNo36 minNoNALung adenocarcinoma tumor extracted DNA(n = 18)Yes99.6% accuracy(0.4% false-negative rate))[98]NPM1 gene c.863_864 4-bp insertions, KIT gene p.W557_K558del, BRAF p.V487_T491del, EGFR p.E746_A750delERA isothermal amplificationengineered AsCas12a protein variantNossDNA-FQ reporter; fluorescent readoutYes30 minNo0.01% VAFsGenomic DNA extracted from the blood cell sample of AML patients(n = 108)YesIdentifies NPM1 mutations in 30 out of 108 AML patients[99]EGFR L858RRPACas12f1NossDNA-FQ reporter; fluorescent readoutNo15-20 min RPA + 30-60 min CRISPR-Cas reactionNo10 copies per microliter (16.8 aM)Formalin-fixed paraffin-embedded (FFPE) NSCLC tumor specimens(n = 22, 12 positive and 10 negative)Yes100% and 100%[100]EGFR E746-A750 mutationLigation-initiated loop-mediated isothermal amplification (LAMP)LbCas12aNoMB-ssDNA monolayer was successfully modified on the surface of the GCE/GDY-AuTNP selectrode,Electro-chemical reporter and readoutNo22-min LAMP + 30-min CRISPR-Cas12a reactionNo17 fMStandard sampleNoNA[101]EGFR L858R, KRAS G12D, and EGFR T790MNAspCas9NANGSNANANANA20 ng reference samplesNo1[102]KRAS G12VCRISPR Cas9 mediated selective RPACas9NASanger sequencingNA20-min incubation timeNANA60 ng genomic DNAYes100% in sample with MAF = 0.1%, 1%, and 5%(n = 3); 70% of the samples with MAF = 0.01%(n = 10)[103]KRAS-G12DRPACRISPR-Cas9 reaction following RCA amplificationNoBiotin probe, HRP-gold nanoparticles complex (hGNPs), colorimetric assayNANANA0.2 fM and 0.01% VAFsSpiked the genome DNA (extracted from the cells stably expressed KRAS-G12D-EGFP) into fetal bovine serum (FBS, 100% and 50%),NoNA[104]EGFR-ΔE746–750, EGFR-L858R, EGFR-T790M and KRAS-G12CRPA/PCRLbCas12aNossDNA-FQ reporter; fluorescent readoutNo50 minNo10 aM and 0.02% VAFsPlasma DNA of NSCLC patients(n = 30)Yes100% and 100%[105]KRAS G12DAsymmetric PCRLbCas12aNossDNA-FQ reporter with a perfect match for WT target and a mismatch for MT target; fluorescent readoutNoNANo0.0001% VAFsHuman genomic DNA extracted from pancreatic cancer samples(n = 15)Yes100% and 100%[106]KRAS G12D, BRAF V600E, EGFRvIII deletion, IDH1R132HNoLwaCas13aself-cascade amplificationRNA–DNA hybrid reporter comprising (1) a fluorescent RNA segment cleavable by Cas13a/crRNA, (2) a fluorescent quencher and (3) a DNA template for target RNA transcription by T7 polymerase; fluorescent readoutYes40 minNoSub-attomolar level, 0.01% VAFsSerum exosome mRNA from different cancer patients(15 non-cancer patients, 107 CRC patients, 60 glioma patients;)Yes100% and 100%[107]PIK3CA 1633G > ANoLbCas12aSelf-cascade amplificationSwitchable-caged guide RNA (scgRNA); Fluorescent readoutYes30 minNo10 aM and 0.1% VAFsGenomic DNA extracted from bladder cancer tissue(n = 6)Yes100% and 100%[14]PIK3CA H1047RRCALbCas12aNossDNA-FQ reporter; fluorescent readoutNo1.5 hNo10 aM and 0.036% VAFsMutant targets of the PIK3CA H1047R (10 fM,100 fM, and 1 pM) were spiked in 5% normal human serumNoNA[108]PTEN R130Q, BRAF V600E, and TP53 R248WSpecific PCRLbCas12aNossDNA-FQ reporter; fluorescent readoutNoNANo0.1% VAFsDNA samples from PCOS and ovarian cancer patient(n = 6)Yes100% and 100%[109]BRAF V600EBlocker Displacement amplification(BDA)Un1Cas12f(Cas14a)Following T7 exonuclease cleavagessDNA-FQ reporter; fluorescent readoutNoNANo0.1% VAFsGenomic DNA extracted from human colorectal carcinoma cellsNoNA[110]IDH1-R132HRPAFnCas12aNossDNA-FQ reporter; fluorescent readoutNo1 hNoNAGlioma tissue samples. 58 previous frozen tissue and 46 recent fresh tissue samples of adult diffuse gliomaYes91.4%, 95.7%in the frozen sample group;96.1%, 89.7% in the fresh sample group[112]Fusion genesNACas9NANanosequencingNANANANA6 tumor samplesYesNA[115]PML/RARA fusion geneRCAFnCas12aFollowed by intermolecular G- quadruplex confinementssDNA-FQ reporter; fluorescent readoutNoNANo0.86 fMFusion gene concentration spiked in 1% human serumNoNA[116] BCR::ABL1 PCRCas13aNAssRNA-FQ reporter; fluorescent readoutNoNANoNARNA was extracted from 10 million cells in total with the number of HL-60 cellsNoNA[117] BCR::ABL1 RT-RPALwaCas13aFollowing T7 transcriptionssRNA-FQ reporter; fluorescent readoutYes1 hNo10 fMRNA was extracted from dried blood spot of CML patients(n = 44)Yes100% and 100%[118]TP53 p.R273 mutantPCRLbCas12aNossDNA-FQ reporter; fluorescent readout, lateral flow assayNoNANoNAMock cfDNA samples derived from cell cultureNoNA[113]BRCA1 3232A > GRPAAaCas12bNossDNA-FQ reporter; fluorescent readoutNoNANo1aM and 1% VAFsDNA oligos commercially purchasedNoNA[50]cryptic mutations in BRCA1NACas9NASequenced these regions with long reads (> 10 000 bp)NANANANAFreshly grown lymphoblasts were loaded onto a high molecular weight library system (Sage Science, Beverly, Massachusetts, USA) and lysed directly in agarose gelsNoNA[114]FLT3 D835YRestriction enzyme-integrated RPACas12aNAssDNA-FQ reporter; fluorescent readoutNo40 minNo0.001% VAFs80 AML patient blood samplesNo100% and 100%[122]MYD88L265PNodeactivated Cas9 (dCas9)NAOrous anodised aluminium (PAA)-based sensing chip, electrical detectionNo40 minNA1.37 nMBlood/cell/tissue genomic DNA extraction from 13 DLBCL patientsYesNA[123]Melanocortin l receptor (MC1R) T305C, T363C, and G727APCRenAsCas12a40 mM Mg2+ssDNA-FQ reporter; fluorescent readoutNoNANoNASynthesized target geneNoNA[124]GNAQ Q209PAllele-specific PCRAsCas12aNAssDNA-FQ reporter; fluorescent readoutNoNANo10 ctDNA-like copies/mL of human plasmaPlasma samples from metastatic UM patients(n = 4)YesNA[125]Circulating tumor DNAEGFR L858R and BRAF V600ERPALwaCas13aT7 in vitro-transcriptionssRNA-FQ reporter; fluorescent readoutNo > 2 hNo1 aM and 0.1% VAFsMock cfDNA samples with allelic fractions as low as 0.1%NoNA[9]EGFR L858R, EGFR T790M, EGFR exon 19 deletionRPALwaCas13aT7 in vitro-transcriptionssRNA-FQ reporter; Lateral flow readout fluorescent readoutNo30 min-3 hYes2aMPatient-derived cfDNA samplesYesNA[15]EGFR T790M/C797SPCRCas13aNossRNA-FQ reporter; fluorescent readoutNoNANo1% VAFcfDNA extracted from NSCLC plasma samples(n = 140)Yes88.1%&100%[16]Breast cancer gene-1 (BRCA-1)NoCas12aNoA 20 nm sized Au nanoparticle (20-AuNP) and 60 nm sized Au nanoparticle (60-AuNP) connected by a FITC-modified double-strand DNA (dsDNA) and single-strand DNA (ssDNA)No30 minNo0.34 fMcfDNA extracted from cell culture mediaNoNA[122]ctDNA KRASExponentialamplification reaction(EXPAR)LbCas12aNoSignal unit (ssDNA-MB@Fc/ UiO-66-NH2) consisting of methylene blue-modified ssDNA as the biogate to encapsulate ferrocene signal molecules within UiO-66-NH2 nanocarriersNoNANo0.11 fMSimulated cfDNA sample by adding different levels of ctDNA to human serum samples diluted 20 timesNoNA[123]Breast cancer gene-1 (BRCA-1)NoCas12aNoSingle nanoparticle dark-field microscopy (DFM) imagingNo40 minNo0.081 fMSynthetic DNANoNA[124]EGFR (exon 19 deletion, T790M, L858R)Nodeactivated Cas9 (dCas9)NoAllele specific qPCRNANANA0.1% allele frequency18 NSCLC patient-derived cfDNA samplesYes8 out of 13[64]PIK3CA exon 9 mutationNodCas9-sgRNA covalently immobilized on graphene oxide screen printed electrodesNAElectrochemical impedance spectroscopy (EIS) analysisNALinear detection limits between 2 and 20 nM for 120 bp ctDNA’s in 40 sNALinear detection limits between 2 and 20 nM for 120 bp ctDNA’s in 40 sSynthetic ctDNANoNA[125]EGFR L858RNodRNP (dCas9-sgRNA) immobilized on carboxyl microspheresNAElectrochemical readoutNANANA2.86 fM and 0.001%VAFctDNA (EGFR L858R) extracted from plasma samples in NSCLC patients (n = 10)YesAUC = 0.990[126]miRNAmiR-21, miR-196a, miR-451a and miR-1246Rolling-circle amplificationCas12aNoSmartphone-based fluorescence detection and with the lateral-flow format for visual readoutsYes20 min to 3 hNoSingle-digit femtomolarEvs’ RNA isolated from the plasma samples of four control donors and four patients with PDACYesSingle-marker detection yielded modest area under the curve (AUC) values ranging from 0.677 (95% confidence interval (CI), 0.486–0.868) for miR-196a to 0.793 (95% CI, 0.635–0.951) for miR-451a. The EV-Sig panel combining miR-21, miR-451a and miR-1246 greatly improves the diagnostic power to an AUC of 0.853 (95% CI, 0.726–0.979)[17]miR-21NoCas12a(split Cas12a system (SCas12a), consisting of a Cas12a enzyme and a split crRNA)NossDNA-FQ reporter; fluorescent readout, lateral flow assayNo20 min reaction timeNo100 fMPlasma samples obtained from seven individuals (aged 25 to 60 years) diagnosed with cervical cancer and three healthy individuals (aged 25 to 60 years)Yes100% and 100%[18]miR-21,miR-92aExponentialamplification reaction(EXPAR)Cas12j variantsNossRNA-FQ reporter; fluorescent readoutNo10 min reaction timeNo1 fMPlasma samples from lung cancer patients (n = 20) and healthy controls (n = 20)Yes90% sensitivity and 95% specificity for miR-21, and 80% sensitivity and 95% specificity for miR-92a[127]miR-200a and miR-126Dumbbell probe initiated multi-Rolling Circle AmplificationLbCas12aNossRNA-FQ reporter; fluorescent readoutNo30 minNo5.44 pMLung cancer/adjacent/normal tissue specimensYesAUC for miR-200a and miR-126 indistinguishing cancer tissue from adjacent tissue was 0.8800 and 0.8700, while in identifying cancer tissue from normal tissue was 0.8850 and 0.9100, respectively; the combined index of miR-200a and miR-126 exhibited AUC = 0.9300) and cancer vs normal tissue (AUC = 0.9400)[128]miRNA-10bNoLbCas12aNossDNA-FQ reporter; lateral flow assay, fluorescent readoutNoNANo5.53 fMSerum samples from glioma patientsYesNA[129]miRNA-21Ligation-recognition triggered Recombinase Polymerase Amplification (RPA)Cas12aNoFunctional Mango RNA aptamer/TO1-Biotin complexes serve as modular signal catalysts of reportersYes40 minNo3.43 aMPlasma and cell samples derived from patients with breast cancerYesNA[13]miRNA-141NACas12a3D DNA Walker mediated CRISPR/Cas12a cascade signal amplificationElectrochemical readoutNo150 min for hybridization and 30 min for reactionNo0.14 fMDifferent concentrations of the miRNA-141 were added into human serumNoNA[19]miR-122b, miR-21, and let-7aStemloop mediated reverse transcription and RPALbCas12a complexed with short crRNA-18 which contains 18-bp complementary regionNossDNA-FQ reporter; fluorescent readoutNo30 min for reactionNo7.8 aM8 blood samples from cancer patientsYesNA[131]miR-21-5pNoLwaCas13aCRISPR/Cas13a sensing components are encapsulated in liposomes and delivered them into EVs through liposome-EV fusionssRNA-FQ reporter; fluorescent readoutNo30 min for incubationYes, gold microdisk arraysNAPlasma samples from ovarian/mullerian cancer patients (n = 5) and normal healthy controls (n = 3,YesNA[132]miR-21,sub-circHIPK3NoCas13aNossRNA-FQ reporter; fluorescent readoutNoNAYes, polydisperse droplet digital10 aMClinical samples from CRC patients and healthy peopleYesNA[133]miR-21NoCas12a and Cas13aThe surface protein of EVs was detected by Cas12a using antibody-DNA conjugates to transfer the signal of the protein to DNA, while the inner miRNA was analyzed by Cas13a through EV-liposome fusionRNA reporters (green fluorescence),DNA reporters (red fluorescence); fluorescent readoutNo30 min for reactionYes, microfluidic chip containing 188,000 microwells214 EVs/μL31 blood samples, 21 from breast cancer patients and 10 from healthy donorsYesThe specificity and sensitivity for PD-L1 alone were 90 and 57%,respectively,while for miR-21 alone,the specificity and sensitivity were 50and 95%. The concurrent assessment of dual markers PD-L1 and miR-21 on single EVs achieved a specificity of 100%and a sensitivity of 81%[134]Epigenetic aberrationsMethylated SEPT9 (mSEPT9)MSRE treated, RPACas12aNossDNA-FQ reporter; fluorescent readoutNo15 min for reactionNo1 copy/μL and 0.01% methylated SEPT9 can be clearly distinguished from a mixture of excess background gDNAFifty-three cases of exfoliated cervical cells(CEC) samples from 27 patients with cervical cancer and 26 patients with non-cervical cancer were collectedYes100% and 92.3%[138]Methylated SEPT9 (mSEPT9)Multiplex PCR reactionLbCas12aNoOligonucleotide-nanoparticle reporter (Oligo-Nano reporter), fluorescent readoutNo40–60 minNo100 fM and 0.1%Consisting of four tissue DNA samples from CRC patients and 16 healthy human buffy coat DNA samplesYesNA[139]CpG methylationNoCas12aNoNanopore sequencingNANANANAHigh-molecular-weight (HMW) DNA extracted from undifferentiated hiPSCs of patientsYesNA[20]DNA adenine methylation methyltransferase (Dam MTase) activityNoCas12a( TdT-IU-CRISPR/Cpf 1(poly-T tail produced and prolonged in the presence of TdT and dTTP, recognition region of crRNA was designed to contain a 23 bp poly-A sequence.)NossDNA-FQ reporter; fluorescent readoutNo120 min for reactionNo1.26 × 10–3 U/mLDifferent concentrations of Dam MTase (0.003, 0.01 and 0.03 U/mL) were spiked in 10% normal human serumNoNA[140]DNA adenine methylation methyltransferase (Dam MTase) activityDNA Mtase and restriction endonuclease triggered strand displacement amplificationCas12aNossDNA-FQ reporter; fluorescent readoutNoThe reaction times of methylation and GlaI cleavage, SDA, and the trans-cleavage of CRISPR/Cas12a were 40, 80, and 50 min, respectivelyNo2.458 × 10–3 U/mLDifferent concentrations of Dam MTase ( 0.1, 0.5 and 1.0 U/mL) were spiked in 10% normal human serumNoNA[141]Protein biomarkersIL-6 and VEGFT7 RNA polymerase transcriptionCas13aCRISPR/Cas13a signal amplification linked immunosorbent assayssRNA-FQ reporter; fluorescent readoutNoNANo45.81 fg/mL (2.29 fM) for IL-6 and 32.27 fg/mL (0.81 fM) for VEGFAdded human IL-6 to 20% and 100% mouse serumNoNA[21]AFPNoLbCas12aNoMB-invertase; glucose readoutNo1 h incubationNo0.01 μg/mLTen-fold serial dilution of AFP biomarker ranging from 100 μg/mL to 0.01 μg/mL in a 5% human serum solutionNoNA[142]PSACatalyzed hairpin assembly (CHA)Cas12aNoUCNPs-ssDNA-Q, colorimetric readout by ultraviolet detectionNo1 h reactionNo0.01 ng/mLHuman serumNoNA[143]AFPNo, aptamer bindingCas12aNoblack hole quencher-2 (BHQ-2) labeled extremely short reporter (5 nt) is linked onto QDs@ASM, fluorescence readoutNoNANo4.12 pg/mL35 cases of appropriately-diluted human serum samples (venous blood source, Fig. 4A) collected from 25 cases of liver cancer patients [LCPs, diagnosed with abnormal AFP contents (> 9 ng/mL)]YesNA[144]Protease (e.g. Ulp1)NoCas13aMulti-component controlled activation system of Cas13 by N-terminus taggingssRNA-FQ reporter; fluorescent readoutNoNANo48.8 pg/μLCell lysatesNoNA[145]telomerase activityDroplet digital hyperbranched amplificationCas12aNossDNA-FQ reporter; fluorescent readoutNoNANo6.3 cells/ μ LBreast cancer cell lysatesNoNA[146]Small molecule and metabolite biomarkersNAD+, ATPNAD+, ATP activated DNA ligationCas12aNossDNA-FQ reporter; fluorescent readoutNoNANo10 pM for NAD and 50 pM for ATPHeLa cell lysatesNoNA[148]ATPAptamer or DNAzyme incubationCas12aNossDNA-FQ reporter; fluorescent readoutNoNANo87 pMCell lysatesNoNA[149]ATPAptamer incubationCas12aNochemiluminescenceNoNANo84.3 nMDifferent concentrations of ATP were incubated with 10% normal human serum to prepare spiked samplesNoNA[150]ATPAptamer incubation, RCACas12aNossDNA-FQ reporter; fluorescent readoutNo1-2 hNoLinear increase of fluorescence signals in the range of 10–250 μmBlood samples from wildtype and transgenic AD miceNoNA[22]ATPAptamer incubationCas12aNossDNA-FQ reporter; fluorescent readoutNo1 h reactionNo0.47 uMCell lysatesNoNA[23]uric acid and p-hydroxybenzoic acidaTFs bindingCas12aNossDNA-FQ reporter; fluorescent readoutNo5–10 min to get fluorescence if uric acid, in the sample is higher than 250 nMNo10 nMClinical serum samplesYesNA[24] A summary of reported CRISPR diagnostics for cancer biomarkers detection Exponential amplification reaction(EXPAR) Exponential amplification reaction(EXPAR) These conformational transitions serve as a proofreading checkpoint, ensuring that only sufficiently matched targets trigger downstream catalytic activity. Mismatches, particularly within the seed region or mismatch-sensitive regions, destabilize the R-loop and prevent full match and activation [36, 40]. Thus, Full match/R-loop formation not only mediates target recognition but also functions as a molecular switch that allosterically activates nuclease activity. Trans-nuclease activation: allosteric activation and signal amplification First, cis-cleavage of the target nucleic acid occurs upon complete R-loop formation. Cas9 employs two nuclease domains: the HNH domain cleaves the target strand, while the RuvC domain cleaves the non-target strand, resulting in a double-strand break [41]. In contrast, Cas12 contains a single RuvC domain that sequentially cleaves both strands, producing staggered double-strand breaks [42]. Cas13, which targets RNA, utilizes dual HEPN domains to cleave single-stranded RNA substrates [43]. This cleavage activity is tightly coupled to aforementioned conformational activation, ensuring that catalysis occurs only after accurate target recognition. (detailed structural change information added). Second, and more critically for diagnostics, is trans-cleavage (collateral activity). Following target binding and initial cleavage, certain Cas effectors enter a hyperactivated state characterized by nonspecific nucleic acid degradation. Specifically, Cas12 indiscriminately cleaves single-stranded DNA (ssDNA), whereas Cas13 cleaves single-stranded RNA (ssRNA). This phenomenon, termed collateral cleavage, arises from structural rearrangements that render the catalytic site constitutively accessible. In particular, conformational changes near the RuvC active site—such as rearrangements of lid-like structural elements—facilitate unrestricted substrate access and Mg2+-dependent substarte nucleic acids attack [5, 34]. In diagnostic platforms such as DETECTR and SHERLOCK [5, 9], synthetic reporter molecules labeled with fluorophore–quencher pairs are introduced. Upon activation, Cas enzymes cleave these reporters, spatially separating the fluorophore from the quencher and thereby generating a detectable signal. This trans-cleavage activity provides intrinsic signal amplification, as a single target recognition event can trigger the cleavage of numerous reporter molecules, significantly enhancing detection sensitivity. Integrated perspective: coupling structure, kinetics, and function The three phases—target search, binding, and trans-nuclease activation—are tightly coupled through dynamic conformational transitions. The search phase enables rapid scanning with minimal energetic expenditure; Full match/R-loop formation acts as a specificity checkpoint and activation trigger; and the catalytic phase converts molecular recognition into an amplified biochemical signal. From a system-level perspective, the performance of CRISPR diagnostics is governed by multiple interdependent factors, including search kinetics (e.g., PAM density and diffusion dynamics), R-loop stability (e.g., sequence complementarity and mismatch tolerance), and catalytic turnover (e.g., trans-cleavage rates). Notably, PAM recognition, DNA unwinding, and R-loop propagation are often rate-limiting steps, thereby exerting a direct influence on detection speed and sensitivity. Classification of CRISPR diagnostics CRISPR diagnostics operate through three major steps: signal input, conversion, and readout. In a CRISPR-Cas system, the target nucleic acid serves as the input signal; upon recognition, the system activates trans-nuclease activity, which indiscriminately cleaves adjacent nucleic acids modified with a functional reporter group(Fig. 2d), thereby generating a fluorescence or electrochemically active substance for signal readout.Fig. 2Classification of CRISPR diagnostics. a CRISPR-based DNA detection. DNA detection platforms are primarily categorized into two classes: Type I-A systems, which employ CRISPR-Cas3 complexes for sequence-specific DNA interrogation, and Type V systems, which utilize Cas12a for both target recognition and signal amplification through nonspecific ssDNA cleavage. b CRISPR-based RNA detection. RNA detection modalities leverage Type III CRISPR-Cas3 complexes for direct RNA targeting and Type VI systems where Cas13a’s RNA-guided RNase activity triggers collateral cleavage of reporter RNA probes upon target activation. c CRISPR diagnostics based on CRISPR-Cas9 system. dCas9/sgRNA-mediated target recognition and isolation have been incorporated for DNA detection. The recent discovery of Cas9’s trans-nuclease activity in complex with crRNA-tracrRNA has enabled highly efficient detection of both DNA and RNA. d Readouts for CRISPR diagnostics. Detection readouts encompass three principal modalities: fluorescence-based FRET probes, electrochemical biosensors utilizing redox-active substrates, and colorimetric platforms such as AuNP-based lateral flow assays (LFAs). Classification of CRISPR diagnostics. a CRISPR-based DNA detection. DNA detection platforms are primarily categorized into two classes: Type I-A systems, which employ CRISPR-Cas3 complexes for sequence-specific DNA interrogation, and Type V systems, which utilize Cas12a for both target recognition and signal amplification through nonspecific ssDNA cleavage. b CRISPR-based RNA detection. RNA detection modalities leverage Type III CRISPR-Cas3 complexes for direct RNA targeting and Type VI systems where Cas13a’s RNA-guided RNase activity triggers collateral cleavage of reporter RNA probes upon target activation. c CRISPR diagnostics based on CRISPR-Cas9 system. dCas9/sgRNA-mediated target recognition and isolation have been incorporated for DNA detection. The recent discovery of Cas9’s trans-nuclease activity in complex with crRNA-tracrRNA has enabled highly efficient detection of both DNA and RNA. d Readouts for CRISPR diagnostics. Detection readouts encompass three principal modalities: fluorescence-based FRET probes, electrochemical biosensors utilizing redox-active substrates, and colorimetric platforms such as AuNP-based lateral flow assays (LFAs). CRISPR-Cas systems are primarily divided into two classes. The Class I systems, characterized by the effector protein Cas3, involve multiple proteins for nucleic acid recognition and cleavage, respectively. In contrast, the Class II systems function with a single effector Cas protein. Each class is further divided into distinct subtypes based on Cas protein functions: Class I systems typically include type I, III, and IV Cas proteins, while Class II systems generally comprise type II, V, and VI Cas proteins [4]. Among these, the type I-A CRISPR-Cas3 complex and type V Cas12a have been repurposed for double-stranded DNA (dsDNA) detection (Fig. 2a) [5, 44], whereas the type III-A CRISPR-Cas Csm complex and type VI Cas13a have been adapted for RNA detection (Fig. 2b) [9, 45]. Additionally, the recently discovered trans-nuclease activity of Cas9, when complexed with a crRNA–tracrRNA dual RNA, has rendered it a versatile tool for both DNA and RNA detection (Fig. 2c) [46]. Type I-A CRISPR-Cas3-based DNA detection The Type I CRISPR-Cas system protects against invading DNA in two primary steps. First, the Cascade proteins recognize the target dsDNA, triggering conformational changes within the Cascade complex. Second, Cas3 effector proteins are recruited to the Cascade complex and execute nuclease activity on the target DNA [47]. Activation of Cas3 leads to collateral, non-specific cleavage of single-stranded DNA (ssDNA), making it a potential candidate for nucleic acid detection. However, the hyperactive ssDNase activity of Cas3 produces noisy background signals that can result in false-positive outcomes. Recent studies have identified a Type I-A protein variant and a Cascade-Cas3 fusion protein that remain inactive until complete R-loop formation occurs between the dsDNA target and crRNA [44, 48]. Specifically, the HD nuclease domain of Cas3 is unblocked only when complete R-loop formation induces a conformational change in the HEL domain, ensuring effective dsDNA detection. Type V CRISPR-Cas12-based DNA detection CRISPR-Cas12a has emerged as a prominent tool in diagnostics since the first introduction of its indiscriminate nuclease activity on single-stranded DNA substrates upon target binding by Jennifer A. Doudna’s group in 2018. Building on this discovery, the DETECTR platform was developed by integrating isothermal nucleic acid amplification with the collateral cleavage activity of Cas12a. This approach enables highly sensitive DNA detection at the attomolar level [5]. Structurally, Cas12a exhibits a bilobed architecture comprising an N-terminal REC lobe—consisting of the REC1 and REC2 domains connected by the WED domain—and a C-terminal NUC lobe, which includes the PI, BH, RuvC, and Nuc domains. Similar to the Cascade-Cas3 complex, Cas12a’s trans-nuclease activity is allosterically regulated. Target DNA binding triggers conformational changes, where the hybridization of the guide RNA to the target DNA (rather than PAM binding alone) induces a critical shift: the REC2 domain moves away from the NUC lobe, thereby unblocking the RuvC active site. This conformational change is essential for substrate access and for the activation of both cis- and trans-nuclease activities. Following cis-cleavage of target DNA, Cas12a remains bound to the PAM-proximal DNA fragment, maintaining its activated conformation and enabling promiscuous cleavage of non-target ssDNA in trans [7]. Furthermore, other type V Cas proteins—such as Cas14, Cas12b, and Cas12g—have been investigated and repurposed for nucleic acid detection. These enzymes exhibit enhanced PAM recognition flexibility, potentially enabling broader target detection[49–52]. Type III-A CRISPR-Cas-based RNA detection Upon binding a single-stranded RNA (ssRNA) target, the type III CRISPR-Cas Csm complex initiates the production of cyclic oligoadenylate (cOA) via the Palm domain of Cas10 subunit. Specifically, the Csm complex begins cA6 synthesis by utilizing three distinct adenosine anchoring sites characterized by Tyr/Ser(Thr) pairs. Two of these sites are shared with cA4-producing Cas10, while the third Tyr/Thr pair is unique to cA6-producing Cas10. This synthesis process involves a 3′ to 5′ nucleotidyl transfer, wherein the 3′-OH group of ATP1 attacks the α-phosphate of ATP2, resulting in the formation of pppA2. This reaction is repeated, sequentially adding adenosine residues until pppA6 is formed and subsequently cyclized [53]. The produced cOA then binds to downstream effectors—including proteases, NucC nucleases, and Csm6—via their CARF domains. Among these effectors, Csm6, a homodimeric enzyme with both CARF and HEPN domains, exhibits allosterically regulated RNase activity. Binding of cyclic hexa-AMP (cA6) to the CARF domain triggers a conformational change that activates the HEPN domains, thereby forming a composite RNase active site capable of promiscuously cleaving non-target RNA [54]. This mechanism is exploited for RNA detection, including SARS-CoV-2 detection on the SHERLOCKv2 platform [15, 45, 55]. Type VI CRISPR-Cas13-based RNA detection The CRISPR-Cas13a system was the first among all CRISPR-Cas systems to be identified with trans-nuclease activity in 2016, capable of non-specific single-stranded RNA (ssRNA) cleavage upon target ssRNA recognition [34]. Structurally, Cas13a exhibits a bilobed architecture comprising a recognition (REC) lobe and a nuclease (NUC) lobe. The repeat region of the crRNA is anchored within the REC lobe, while the guide-target RNA duplex is positioned within a binding channel in the NUC lobe. Upon target RNA binding, conformational changes occur, widening this binding channel and activating the HEPN catalytic site. Specifically, the HEPN1 domain rotates toward the HEPN2 domain, bringing the catalytic residues into proximity, thereby facilitating RNA cleavage. This activation results in the non-specific cleavage of ssRNA [8]. Leveraging this system, Feng Zhang’s group developed the SHERLOCK platform, enabling RNA detection with attomolar sensitivity [9]. CRISPR diagnostics based on type II CRISPR-Cas9 system The Type II CRISPR-Cas9 system is the most well-known for its widespread use in gene-editing field [28]. In the context of nucleic acid detection, researchers employed nuclease-deactivated Cas9 proteins (dCas9) as probes to label and enrich target nucleic acids by specifically binding to target sequences without inducing cleavage [56, 57]. Recently, Chen et al. reported that Cas9 enzyme also exhibited RuvC domain-dependent trans-nuclease activity, especially when complexed with crRNA-tracrRNA dual RNAs. This collateral cleavage activity can be triggered by target ssDNA, double-stranded DNA (dsDNA), and ssRNA [46]. This discovery has expanded the versatility of the CRISPR-Cas9 system, positioning it as a promising tool for nucleic acid detection. Historic perspectives of CRISPR diagnostics The evolution of CRISPR-based diagnostics can be delineated across a unified timeline defined by key technological breakthroughs, rather than by discrete periods tied to the COVID-19 pandemic. This framework organizes the progression of the field into three coherent stages: the foundational era (2012–2019), marked by the discovery and repurposing of CRISPR systems for diagnostic applications; the pandemic era (2019–2023), characterized by rapid innovation driven by the urgent need for scalable and deployable testing solutions; and the post-pandemic era (2023–present), focused on enhancing diagnostic performance, multiplexing capabilities, and point-of-care adaptability (Fig. 3). Fig. 3A comparative timeline highlights evolutionary milestones of CRISPR diagnostics. A schematic representation delineating the chronological development of CRISPR diagnostic platforms over the past decade, encompassing: Cas9 (green), Cas12a (red), and Cas13a (orange) nuclease-mediated detection systems characterized by their distinct enzymatic mechanisms (DNA/RNA-guided trans-cleavage activities) and Class I CRISPR-Cas systems (e.g., Type I-A Cas3 complexes, blue) employing multi-subunit effector assemblies for target detection. A comparative timeline highlights evolutionary milestones of CRISPR diagnostics. A schematic representation delineating the chronological development of CRISPR diagnostic platforms over the past decade, encompassing: Cas9 (green), Cas12a (red), and Cas13a (orange) nuclease-mediated detection systems characterized by their distinct enzymatic mechanisms (DNA/RNA-guided trans-cleavage activities) and Class I CRISPR-Cas systems (e.g., Type I-A Cas3 complexes, blue) employing multi-subunit effector assemblies for target detection. The foundational era (2012–2019) In 2012, a groundbreaking study by Jennifer A. Doudna, Emmanuelle Charpentier, and colleagues demonstrated that the bacterial CRISPR-Cas9 system could be repurposed as a programmable tool for precise DNA cleavage [28]. This discovery marked the advent of CRISPR-Cas9 as a transformative gene-editing technology, ultimately awarding Doudna and Charpentier the Nobel Prize in Chemistry in 2020. Subsequently, deactivated Cas9 (dCas9) proteins, which retain target-binding capability but lack nuclease activity, have been repurposed for target genomic loci labeling and imaging by various researchers [56–58]. A pivotal breakthrough for CRISPR technology in molecular diagnostics occurred in 2016 with the discovery of the trans-nuclease activity of Cas13a [34], propelling CRISPR-based diagnostics into a new era. Since then, CRISPR diagnostics have undergone rapid advancements. The discovery of Cas13a’s trans-nuclease activity in October 2016 marked a paradigm shift in nucleic acid detection, ushering in the era of CRISPR diagnostics. This breakthrough enabled the development of the SHERLOCK platform, which combined CRISPR-Cas13a’s collateral RNA cleavage activity with isothermal amplification techniques to achieve unprecedented rapidity, field deployability and sensitivity [5, 9, 15, 34, 59]. While standalone CRISPR-Cas systems demonstrated picomolar (pM)-level sensitivity for nucleic acid detection [3], integrating them with isothermal amplification methods enhanced detection limits to the attomolar (aM) range. For instance, HyperCas—a biosensor combining hyper-branching rolling circle amplification (HRCA) with Cas13a’s collateral cleavage activity—achieved ultrasensitive microRNA detection at the 200 aM level [60]. The introduction of SHERLOCKv2 further expanded the utility of Cas13-based platforms through four transformative innovations: (1) multiplexing capability: by leveraging orthogonal CRISPR enzymes (e.g., LwaCas13a, PsmCas13b, AsCas12a) with distinct dinucleotide cleavage preferences, SHERLOCKv2 enabled simultaneous detection of up to four targets, such as Zika/Dengue RNA and bacterial genes, in a single reaction. (2) Quantitative precision: optimized RPA protocols achieved attomolar sensitivity (as low as 2 aM) with a linear correlation between input nucleic acid concentration and signal intensity, facilitating quantitative analysis. (3) Signal Amplification: the incorporation of Csm6, an auxiliary nuclease activated by Cas13-generated RNA fragments, enhanced sensitivity by 3.5-fold and accelerated detection kinetics. (4) Portable readout: integration with lateral-flow strips allowed instrument-free, visual interpretation of results [15]. The trans-nuclease activity of the Cas12a enzyme was discovered in 2018, leading to the development of the Cas12a-based DETECTR method for DNA detection [5]. Several novel Type V Cas enzymes have also been identified with collateral nuclease activity, enabling the development of innovative nucleic acid detection methods. HOLMESv2, a one-pot detection system combining loop-mediated isothermal amplification (LAMP) with Cas12b’s trans-nuclease activity, demonstrated robust nucleic acid quantitation [61]. Other methods such as Cas12b-based CDetection [50] and Cas14-DETECTR [49] can realize high-fidelity SNP genotyping at the single-base resolution. Yan et al. further investigated the functional diversity of Type V CRISPR-Cas systems, revealing that Cas12c, -h, and -i exhibit RNA-guided double-stranded DNA (dsDNA) interference activity, while Cas12g functions as an RNA-guided ribonuclease (RNase) with collateral RNase and single-stranded DNase activity. This suggests that Cas12g has potential as a novel CRISPR diagnostic tool [51]. Beyond its traditional role in gene editing, the CRISPR-Cas9 system has been repurposed for molecular diagnostics. By retaining its sequence-specific targeting capability while eliminating its nuclease activity through the use of deactivated Cas9 (dCas9) proteins, researchers have developed novel diagnostic applications. Kyeonghye Guk et al. introduced a CRISPR-mediated DNA fluorescence in situ hybridization (FISH) method based on the dCas9/sgRNA complex. This approach enables the sensitive detection of the methicillin-resistant Staphylococcus aureus (MRSA) target gene within 30 min, without requiring polymerase chain reaction (PCR) amplification or gene purification steps [62]. Similarly, Yodai Takei et al. combined dCas9-EGFP-mediated genomic tracking with DNA labeling via sequential fluorescence in situ hybridization (seqFISH). This technique allowed for the visualization of telomere region dynamics, enhancing our understanding of chromosome organization [63]. Furthermore, dCas9 proteins complexed with sgRNAs have been used to detect mutations in cell-free DNA (cfDNA) samples. After incubation, the captured DNA can be isolated and further identified [64]. In addition, within the nanopore sequencing platform, the binding of the dCas9/sgRNA complex to target DNA disrupts ionic current signals. This disruption allows for the detection of DNA sequences with high specificity [65]. dCas9 proteins have also been utilized for microRNA detection. The first CRISPR-Cas9-based microRNA detection platform incorporated isothermal amplification via rolling circle amplification (RCA). This method involved specific site binding by two dCas9 proteins tagged with split horseradish peroxidase (HRP) halves, facilitating colocalization and subsequent colorimetric readout [66]. Moreover, the CRISPR-Cas9 system has been adapted for novel sequencing technologies. A technique called FLASH (Finding Low Abundance Sequences by Hybridization) enables the cost-effective detection of antimicrobial resistance genes. In this approach, genomic DNA is initially treated with phosphatase to block it, then selectively cleaved by a Cas9 complex paired with guide RNAs. Sequencing adaptors are subsequently ligated, followed by amplification and sequencing, allowing for the precise identification of low-abundance target genes amidst high-background noise [67]. The pandemic era (2019–2023) The global COVID-19 pandemic accelerated the evolution of CRISPR diagnostics, driven by the urgent need for rapid, accurate, and scalable testing solutions. Following the FDA’s emergency authorization for the SHERLOCK-based SARS-CoV-2 detection kit in May 2020, significant advancements emerged. Patchsung et al. validated SHERLOCK for SARS-CoV-2 detection with a limit of detection (LoD) of 42 RNA copies per reaction and 100% concordance with gold-standard quantitative PCR, demonstrating clinical reliability [68]. Fozouni et al. eliminated the need for pre-amplification by coupling Cas13a with a mobile phone-based microscopy readout, achieving 100 copies/μL sensitivity within 30 min—a milestone for point-of-care testing [69]. Ackerman et al. developed CARMEN (Combinatorial Arrayed Reactions for Multiplexed Evaluation), a revolutionary system utilizing color-coded droplets in microwell arrays to enable multiplex detection of Zika virus, influenza A subtypes, and HIV drug resistance mutations. CARMEN’s scalability was further enhanced by the mChip, accommodating > 170,000 reactions per chip [70]. Welch et al. advanced CARMEN to mCARMEN (microfluidic CARMEN), which integrated automated RNA extraction and single-step amplification to process 300–550 samples daily. This system improved SARS-CoV-2 variant detection and dual Cas12/Cas13 workflows, achieving clinical validation in Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories [71]. In addition, SHINEv.2 addressed operational challenges through lyophilized reagents stable at 25 °C for > 1 week and an extraction-free protocol using FastAmp Viral Solution, bypassing nucleic acid purification to enable decentralized testing in resource-limited settings [72]. In April 2020, Broughton et al. introduced DETECTR, a CRISPR-Cas12-based assay for rapid SARS-CoV-2 detection. The assay integrates RT-LAMP for isothermal amplification with Cas12 detection, yielding results within 30–40 min with comparable accuracy to qRT-PCR. Clinical validation using respiratory swab samples demonstrated a high positive predictive agreement (95%) and negative predictive agreement (100%) with the qRT-PCR assay [73]. This method’s rapid turnaround time and ease of use underscore its potential for point-of-care testing, particularly in resource-limited settings. Subsequent SARS-CoV-2 detection methods based on the CRISPR-Cas12a system aimed to enhance sensitivity and specificity for multiplexed nucleic acid detection and point-of-care testing. For example, by leveraging isotachophoresis (ITP) technology on a microfluidic chip, CRISPR-Cas12a reagents, target nucleic acids, and FQ-ssDNA reporters were concentrated for automated reactions and readouts. This approach also facilitated rapid nucleic acid extraction from raw swab samples, reduced the total detection time to 35 min [74]. The All-In-One Dual CRISPR-Cas12a (AIOD-CRISPR) assay integrated RPA isothermal amplification with a CRISPR-Cas12a system containing two crRNAs targeting distinct nucleoprotein genes of SARS-CoV-2. This method achieved clinical sample detection within 20 min using a low-cost hand warmer for incubation, making it highly accessible for point-of-care testing [10]. Another approach involved pre-loading CRISPR reagents in the tube lid while sealing RT-LAMP reagents at the bottom with mineral oil. Following RT-LAMP amplification, simple handshaking mixed the reaction components, completing nucleic acid detection within 40 min with a limit of detection of 20 RNA copies while preventing environmental contamination [75]. Further innovations included optimizing reaction conditions to enhance sensitivity. Ma et al. demonstrated that manganese ions increased detection sensitivity by up to 13-fold, enabling the detection of target RNAs as low as five copies and distinguishing single nucleotide polymorphisms [76]. The first digital CRISPR-Cas12a-based virus detection method, deCOViD, enabled qualitative detection within 15 min and quantitative detection within 30 min by integrating CRISPR-Cas12a-assisted RT-RPA on microfluidic digital chips [11]. Additionally, a smartphone-based fluorescence microscope mounted on a polydimethylsiloxane (PDMS) chip facilitated viral load quantification with a detection limit of 0.38 copies/μL in just 15 min [77]. An engineered AsCas12a protein variant (E174R/S542R/K548R) coupled with DNA-RNA hybrid guides significantly enhanced signal output, allowing for point mutation detection of SARS-CoV-2 at the 2–40 copies/μL level under 30 min [78]. Interestingly, Lu et al. discovered that using crRNAs targeting suboptimal PAM sequences (e.g., ‘NTTV’ and ‘TTNT’ instead of ‘TTTV’) in a one-pot reaction system containing RPA and CRISPR-Cas12a accelerated the reaction rate by 2- to threefold due to buffered cis-cleavage of target amplicons [79]. Significant advancements in Cas9-assisted sequencing were also made during the SARS-CoV-2 pandemic. In February 2020, Gilpatrick et al. introduced a targeted nanopore sequencing method known as nCATS (nanopore Cas9-targeted sequencing). This approach employed Cas9 proteins to cleave genomic DNA at targeted sites, enabling adapter ligation and sequencing. By using multiple guide RNAs targeting the same genomic locus, this method improved median coverage and facilitated the analysis of genomic abnormalities, including point mutations and structural variations. Additionally, because nanopore sequencing directly interrogates DNA strands rather than relying on sequencing by synthesis, it allows for the simultaneous profiling of DNA methylation at specific loci [80]. For multiplexed detection, Gu et al. developed CRISPRmap, a multimodal optical pooled CRISPR screening method. This technique enables the simultaneous detection of multiple biomarkers, including mRNA and protein expression. By visually mapping the correlation between genetic perturbations and spatial multi-omics changes at the cellular and tissue levels, CRISPRmap significantly expands the scope of CRISPR-based detection. It extends beyond conventional nucleic acid detection to include the analysis of cellular morphology and tissue architecture variations [81]. In August 2022, Hu et al. elucidated the mechanism underlying the Type I-A CRISPR-Cas system from Pyrococcus furiosus (Pfu) and repurposed it as a nucleic acid detection tool, termed HASTE. Unlike other Type I systems, the Pfu Cascade complex and Cas3 form an integrated structure in which Cas3’s nuclease activity is allosterically activated by Cascade upon the completion of R-loop formation. HASTE capitalizes on this mechanism, wherein target DNA recognition by the Cascade-Cas3 complex triggers Cas3’s collateral single-stranded DNA (ssDNA) cleavage activity. This enzymatic activity results in the cleavage of a fluorophore-quencher-labeled ssDNA reporter, generating a fluorescent signal. The system enables the direct detection of both double-stranded DNA (dsDNA) and ssDNA at picomolar concentrations within 15 min, eliminating the need for polymerase chain reaction (PCR) amplification. Furthermore, HASTE is heat-activatable, facilitating simultaneous sample inactivation and nucleic acid detection, thereby streamlining the diagnostic workflow [44]. The post-pandemic era (2023–present) Post-pandemic advancements have focused on optimizing diagnostic performance. Vargas et al. revealed that shorter crRNA spacers (16–20 nt) improved mismatch discrimination in Cas13a, while engineered variants (e.g., N378A) and algorithmic crRNA design (e.g., mismatches at position 28) enhanced specificity for pathogen detection [82, 83]. The development of aggregation-induced emission luminogen (AIEgens)-modified dsDNA reporters with Black Hole Quencher (BHQ)-quenched probes achieved an 80-fold sensitivity boost over traditional fluorescence-quenched (FQ) reporters [84]. Towards Point-of-Care Testing (POCT), Wang et al. devised a one-pot reaction system using nested tubes to physically separate amplification and detection phases. By centrifuging pre-loaded reagents into a single chamber, this approach enabled visual readouts without cross-contamination risks, exemplifying user-friendly, field-deployable diagnostics [85]. Following the pandemic, CRISPR-Cas12-based diagnostics have progressed toward improved diagnostic efficacy. Recent efforts have focused on optimizing crRNA design and reporter engineering. Hu et al. addressed the low-sensitivity challenge caused by Cas protein cis-activity in a single-tube reaction by developing a photo-controlled crRNA with a photocleavable (PC)-linker to silence the crRNA. This light-triggered activation strategy enhanced sensitivity by 2–3 orders of magnitude[86]. Systematic screening of Cas12a orthologs paired with engineered crRNAs (e.g., truncated or loop-modified structures) revealed significantly improved trans-nuclease activity [87]. Additionally, split crRNAs enabled Cas12a to detect RNA at femtomolar levels without pre-amplification while improving mutation discrimination [18]. Reporter engineering has further advanced detection limits. Extending poly-T reporters from 5 to 13 nucleotides significantly increased Cas12a trans-activity [88]. Zhou et al. combined chemiluminescence with a quadruple amplification cascade (RCA, Cas12a, CuS/AgNO3 exchange, luminol-H2O2), achieving attomolar miRNA detection [89]. Furthermore, framework nucleic acids (FNAs) optimized local reporter density, allowing femtomolar detection within 15 min without amplification [90]. Efforts toward contamination-free, one-step CRISPR-based detection methods have also gained recognition. Lin et al. integrated RPA with CRISPR-Cas12a for non-PAM target recognition, enabling a single-pot reaction that allowed for naked-eye detection within 30 min, with single-copy sensitivity and single-nucleotide discrimination specificity [91]. Additionally, crRNA acylation, which suppresses crRNA function until restored via brief light exposure, has facilitated efficient one-pot detection [92]. An amplification-free method, the AutoCAR system, utilized autocatalytic Cas12a circular DNA amplification to enable SNP mutation detection at the attomolar level within 15 min at room temperature without requiring nucleic acid pre-amplification [93]. A major breakthrough occurred in May 2024 with the discovery of the trans-nuclease activity of Cas9 enzymes. This property had previously gone unnoticed due to the widespread use of engineered single guide RNAs, which engineered the natural crRNA/tracrRNA into a single guide RNA for gene editing applications. When coupled with crRNA and trans-activating RNA (tracrRNA), the RuvC domain of Cas9 exhibits prominent trans-cleavage on single-stranded DNA (ssDNA) or RNA substrates. This trans-nuclease activity has been harnessed to develop novel DNA and RNA detection platforms, termed DACD (DNA-activated Cas9 degradation) and RACD (RNA-activated Cas9 degradation), respectively [46]. Compared to nucleic acid detection methods based on Cas12a and Cas13a, Cas9’s trans-nuclease activity-based detection offers several advantages. It exhibits reduced dependency on protospacer adjacent motif (PAM) or protospacer flanking sequence (PFS) recognition, thereby enabling broader substrate selectivity for both DNA and RNA targets. This enhanced versatility makes Cas9’s trans-nuclease activity-based detection a powerful tool for DNA and RNA diagnostics. Although the World Health Organization (WHO) declared the end of the COVID-19 global Public Health Emergency (PHE) in May 2023, nucleic acid detection technologies for pathogens, including SARS-CoV-2, continue to advance, with applications extending beyond infectious diseases. Validated during the pandemic, CRISPR-based diagnostic platforms have demonstrated remarkable sensitivity and specificity, fostering significant progress in the detection of single nucleotide polymorphisms (SNPs), microRNAs, circulating nucleic acids, and even non-nucleic acid biomarkers. Notably, these advancements have been particularly foundational in the field of cancer diagnostics, highlighting the broad potential of CRISPR technologies in molecular medicine. CRISPR diagnostics for cancer The sequence-specific recognition mediated by guide RNAs, coupled with target-triggered trans-nuclease activity, enables the conversion of rare molecular events into amplified and quantifiable signals. This unique signal transduction paradigm is particularly well suited for oncology, where clinically relevant biomarkers—such as low-frequency somatic mutations, circulating tumor DNA (ctDNA), and microRNAs—are often present at low abundance in complex biological matrices. Compared with established clinical technologies such as quantitative PCR (qPCR), next-generation sequencing (NGS), and immunoassays, CRISPR-based diagnostics offer several distinct advantages. First, their intrinsic single-nucleotide resolution enables precise discrimination of oncogenic mutations without the need for extensive sequencing workflows. Second, the collateral cleavage-mediated signal amplification allows rapid detection with minimal instrumentation, facilitating deployment in point-of-care and resource-limited settings. Third, the modularity of CRISPR systems permits seamless integration with diverse upstream amplification strategies and downstream readout modalities, supporting flexible assay design across a wide range of biomarker classes. Importantly, these features position CRISPR diagnostics as a complementary technology to existing clinical methods, with particular strengths in rapid screening, decentralized testing, and detection of low-abundance targets in liquid biopsy applications. Building on these advantages, CRISPR-based diagnostic developments have rapidly expanded across diverse biomarker types in oncology. At the nucleic acid level, their ability to discriminate single-nucleotide variations enables precise identification of key genetic aberrations, including point mutations, deletions, oncogenic fusion genes, and chromosomal rearrangements (Fig. 4a). Beyond nucleic acid targets, advances in amplification strategies and Cas enzyme engineering have enabled the detection of trace amounts of circulating tumor DNA (ctDNA) (Fig. 4b) and microRNA (miRNA) (Fig. 4c) in blood. Furthermore, integration with bisulfite treatment, methylation-sensitive restriction enzyme (MSRE) analysis, and functional nucleic acid technologies—such as aptamers, DNAzymes, and allosteric transcription factors (aTFs)—has extended the reach of CRISPR diagnostics to non-nucleic acid biomarkers, including epigenetic alterations (Fig. 4d), protein biomarkers (Fig. 4e), and small-molecule metabolites (Fig. 4f). These developments underscore the growing role of CRISPR platforms in addressing key clinical needs, including early detection, treatment selection, and minimal residual disease monitoring. Fig. 4CRISPR diagnostics for cancer biomarkers detection. a, b Mutation and circulating tumor DNA (ctDNA) detection: allele specific endonuclease digestion to eliminate wildtype allele, selective binding and enrichment of mutant allele by CRISPR-dCas9 system and introduction of PAM sequence in pre-amplification process enable mutant allele enrichment to activate Cas enzymes complexed with optimally mismatched crRNA for trans-cleavage and downstream readouts. c miRNA Profiling: Target miRNAs initiate rolling circle amplification (RCA) to generate single-stranded DNA concatemers, which activate trans-nuclease activity of Cas enzymes via programmable crRNA recognition; d Epigenetic Analysis: Bisulfite-mediated cytosine deamination or methylation-sensitive restriction enzymes (MSREs) selectively convert methylated targets into amplifiable templates for CRISPR-Cas system recognition and activation. e Protein Biomarker Detection: Protease-activated Cas systems utilize SUMO-tagged effectors that release active Cas enzymes upon tumor protease cleavage to complex with crRNA and target for signal reporter cleavage in trans. Parallel approaches employ functional nucleic acids (e.g. aptamers) to convert protein levels (e.g., AFP, PSA) into CRISPR-activatable DNA signals. f Small molecule and metabolite biomarkers detection. Synthetic nucleic acid transducers (e.g. aptamers, DNAzyme and allosteric transcription factors) bind metabolites, triggering toehold-mediated strand exchange or DNAzyme cleavage to generate amplifiable surrogate sequences for Cas12a/Cas13 readouts. CRISPR diagnostics for cancer biomarkers detection. a, b Mutation and circulating tumor DNA (ctDNA) detection: allele specific endonuclease digestion to eliminate wildtype allele, selective binding and enrichment of mutant allele by CRISPR-dCas9 system and introduction of PAM sequence in pre-amplification process enable mutant allele enrichment to activate Cas enzymes complexed with optimally mismatched crRNA for trans-cleavage and downstream readouts. c miRNA Profiling: Target miRNAs initiate rolling circle amplification (RCA) to generate single-stranded DNA concatemers, which activate trans-nuclease activity of Cas enzymes via programmable crRNA recognition; d Epigenetic Analysis: Bisulfite-mediated cytosine deamination or methylation-sensitive restriction enzymes (MSREs) selectively convert methylated targets into amplifiable templates for CRISPR-Cas system recognition and activation. e Protein Biomarker Detection: Protease-activated Cas systems utilize SUMO-tagged effectors that release active Cas enzymes upon tumor protease cleavage to complex with crRNA and target for signal reporter cleavage in trans. Parallel approaches employ functional nucleic acids (e.g. aptamers) to convert protein levels (e.g., AFP, PSA) into CRISPR-activatable DNA signals. f Small molecule and metabolite biomarkers detection. Synthetic nucleic acid transducers (e.g. aptamers, DNAzyme and allosteric transcription factors) bind metabolites, triggering toehold-mediated strand exchange or DNAzyme cleavage to generate amplifiable surrogate sequences for Cas12a/Cas13 readouts. Mutation detection: enabling rapid and high-resolution genotyping EGFR Epidermal growth factor receptor (EGFR) mutations, including point mutations (e.g., T790M, L858R) and exon 19 deletions (e.g., E746-A750), are established biomarkers for risk stratification and targeted therapy in non-small cell lung cancer (NSCLC). However, clinical detection is often challenged by low speed and variant allele fractions (VAFs) constraints. CRISPR-Cas systems have been increasingly adapted to overcome these limitations, enabling highly sensitive and specific genotyping directly from clinical specimens. In 2021, Yu et al. developed a double-stranded DNA probe strategy that bypasses PAM restrictions for single-nucleotide polymorphism (SNP) detection. By designing a double-stranded PAM scaffold with a single-stranded overhang complementary to the target, this approach achieved 10 aM sensitivity and 0.1% VAF specificity for EGFR T790M, albeit with a multi-step workflow [94]. To streamline clinical application, CASMART integrated recombinase polymerase amplification (RPA) and CRISPR-Cas12a into a one-tube assay, enabling digital quantification of mutant-to-wildtype ratios within one hour using 20,000-nanoliter chamber arrays [12]. Further innovations include leveraging dCas9 for electrophoretic mobility-based discrimination of point mutations [95] and combining blocker displacement amplification (BDA) with temperature-optimized Cas12a reactions to detect EGFR L858R at < 0.01% VAF [13]. For enhanced specificity, Liu et al. utilized allele-specific PCR and single-base extension to translate point mutation information into ssDNA activator length differences (14nt vs. 15nt), enabling Cas12a to distinguish EGFR T790M at 0.002% VAF [96]. Similarly, MscI restriction enzyme digestion was utilized to selectively cleave wildtype EGFR L858R alleles, improving mutant enrichment [97]. Systematic optimization of Cas12a trans-cleavage conditions revealed that a "5C" reporter enhanced activity ninefold over conventional “TTATT” reporters, while excess dsDNA competitively inhibited cleavage efficiency [98]. To address simultaneous detection of 16 deletion subtypes (45% of EGFR-mutated NSCLC), Liu et al. developed CoHIT, a multiplexed isothermal assay using hyper-tolerant AsCas12a variants (E174R, M537R) for detecting multiple same-site indels [99]. Novel Cas orthologs and biosensor platforms have further expanded clinical utility. Cas12f1, traditionally activated by ssDNA/RNA, was engineered for dsDNA targeting through sgRNA modifications such as tracrRNA truncation and polyU tailing, achieving a tenfold improvement in specificity for EGFR L858R [100]. Electrochemical platforms integrating nanomaterials such as gold nanoparticles and graphdiyne with LAMP-CRISPR systems enabled fluorescence-free detection of E746-A750 deletions, facilitating point-of-care applications [101]. KRAS KRAS G12 mutations, including dominant subtypes G12C, G12D and G12V, are pivotal oncogenic drivers across malignancies. To enhance detection in clinical samples, CRISPR-Cas systems have been tailored for single-nucleotide precision. Selective cleavage of wildtype alleles by the CRISPR-Cas9 system through the introduction of PAM-proximal mismatches helps enrich mutant templates, reducing false positives in sequencing or pre-amplification [102–104]. Cas12a-based diagnostic methods exploit suboptimal PAM sequences (e.g., “GTTG” near KRAS G12C) to bypass PAM constraints, achieving 100 aM sensitivity and 0.02% variant allele frequency (VAF) in lung cancer [105]. Hu et al. devised a triple mismatch differentiation (TMD) strategy: two crRNA-target mismatches suppress Cas12a’s trans-cleavage activity towards wildtype targets, while a destabilized reporter duplex containing a single-site mismatch between the single-stranded reporter and target further enhances mutant-specific signals, achieving unprecedented 0.0001% VAF specificity [106]. Liquid biopsy applications are emerging for early screening. Song et al. developed a Cas13a-based platform to profiles mRNA mutation in circulating extracellular vesicles (EVs). By incorporating a self-amplification cascade circuit, this approach enabled discrimination of KRAS G12D mutations at sub-attomolar levels without pre-amplification, and correlated KRAS G12D levels with colorectal cancer recurrence in both mouse models and patients [107]. PIK3CA PIK3CA hotspot mutations (e.g., H1047R, E545K, E542K), prevalent in colorectal, breast, and other cancers, are critical biomarkers for prognosis and targeted therapies. In 2021, Shi et al. developed CONAN (CRISPR-Cas-Only Amplification Network), a self-sustaining CRISPR-Cas12a system leveraging a positive feedback nucleic acid circuit. The system employs a “caged” guide RNA (gRNA) hybridized with a blocker ssDNA. Upon target recognition, activated Cas12a cleaves the blocker, releasing the gRNA to bind and activate additional pre-loaded Cas12a proteins, thereby initiating an exponential amplification cascade. This autonomous feedback loop enabled 10 aM sensitivity and 0.1% variant allele frequency (VAF) specificity for detecting PIK3CA_1633G>A in genomic DNA extracted from bladder cancer tissue [14]. Separately, CRISPR-Cas12a coupled with rolling circle amplification (RCA) achieved 0.036% VAF sensitivity for H1047R detection, using a circular probe with a single-base gap that selectively incorporated dCTP only when bound to mutant DNA [108]. BRAF The BRAF V600E mutation, a key therapeutic target in melanoma, NSCLC, and other solid tumors, necessitates rapid detection to guide BRAF inhibitor therapies. One study devised a hairpin-structured primer for allele-specific PCR amplification by exploiting differential binding free energy between wildtype and mutant sequences, selectively enriching mutant templates for subsequent CRISPR-Cas12a detection while bypassing PAM limitations, achieving 100% sensitivity and 100% specificity in DNA samples obtained from patients with polycystic ovary syndrome (PCOS) and ovarian cancer [109]. A comparative survey of Type V CRISPR systems revealed Cas14a’s superior specificity over Cas12a for BRAF SNP discrimination. When integrated with blocker displacement amplification (BDA), Cas14a achieved 0.5% variant allele frequency (VAF) sensitivity, enhancing clinical utility for low-abundance mutation detection [110]. IDH1 IDH1 mutation status is a critical biomarker for glioma stratification according to the 2021 WHO classification of central nervous system tumors [111], necessitating rapid and accurate diagnostic approaches. A study validated that CRISPR-Cas12a-based detection of the IDH1 R132H mutation demonstrates superior speed compared to immunohistochemistry (IHC) and next-generation sequencing (NGS), while retaining diagnostic accuracy with a sensitivity and specificity of 91.4% and 95.7%, respectively, in the frozen sample group, and 96.1% and 89.7%, respectively, in the fresh sample group, using glioma tissue samples [112]. Furthermore, the recently developed SCOPE system extends CRISPR utility to mRNA-level IDH1 R132H detection in surgical glioma specimens, enhancing intraoperative molecular stratification [107]. TP53 Kohabir et al. demonstrated that Cas12a’s native PAM sequence (TTTV), fortuitously positioned -5 nucleotides upstream of TP53 R273 hotspot mutations, allows discrimination of multiple R273 point mutations even outside its canonical seed region (5–6 nt downstream of PAM). Unmodified LbCas12a outperformed other variants in specificity, while reducing pre-amplification PCR cycles to 25 further enhanced mutant allele resolution [113]. In parallel, a hairpin primer-based strategy selectively suppressed wildtype TP53 R248W amplification during PCR by introducing mismatches, enabling subsequent Cas12a detection with 100% accuracy in clinical samples. This method also detected PTEN R130Q mutations at 0.1% variant allele frequency (VAF), highlighting its versatility [109]. BRCA1 In 2019, CDetection, a Cas12b-based platform, demonstrated superior sensitivity over Cas12a by incorporating guide RNAs with dual mismatches (one mismatch at mutant site and additional single-nucleotide mismatch) to discriminate BRCA1_3232A>G and BRCA1_3537A>G from wildtype alleles. Coupled with RPA pre-amplification, it achieved sub-attomolar sensitivity [50]. Separately, Walsh et al. identified a cryptic BRCA1 mutation inducing pseudo-exon formation via Cas9-mediated precision excision of the entire BRCA locus followed by long-read sequencing, revealing premature transcriptional truncation. This hybrid CRISPR-sequencing approach uncovered structural variants undetectable by conventional methods, highlighting its utility for resolving complex genomic alterations [114]. Oncogenic fusion gene Oncogenic fusion genes (e.g., BCR::ABL1, PML::RARA) serve as both therapeutic targets and diagnostic hallmarks, particularly in leukemias. Stangl et al. developed FUDGE, a fusion gene detection system that uses crRNA near suspected breakpoints to guide Cas9 cleavage. The PAM-proximal side is modified for long-read sequencing, while the PAM-distal side is protected from modification, allowing for targeted sequencing. This method enables detection of fusion genes from genomic DNA within two days, compared to longer turnaround times for WGS and targeted NGS [115]. For enhanced sensitivity, a study reported that using inter-molecular G-quadruplex structures from RCA amplification as a reaction scaffold concentrates Cas12a, enhancing its collateral activity on ssDNA reporters for a higher fluorescence readout and enabling femtomolar sensitivity in detecting PML/RARA genomic fragments [116]. Cullot et al. compared SHERLOCK (a CRISPR-Cas13a system) with PCR for diagnosing the BCR::ABL1 fusion gene and found SHERLOCK had comparable or better sensitivity, making it a viable alternative when PCR instruments are unavailable. In another study, targeting the fusion gene junction with specific crRNA, SHERLOCK achieved 100% accuracy in diagnosing APL and CML by integrating RT-RPA and Cas13a into a one-pot assay, detecting targets within 2 h for RNA samples extracted from dried blood spot of CML patients [117, 118]. Circulating nucleic acid detection: enabling non-invasive cancer monitoring The advent of non-invasive prenatal testing (NIPT) following the discovery of cell-free fetal DNA in maternal circulation marked a transformative milestone in liquid biopsy [119]. While traditional methods such as qPCR and next-generation sequencing (NGS) have enabled the characterization of trace nucleic acids in plasma [120, 121], their limitations in speed and field adaptability have spurred the development of CRISPR-Cas-based detection methods. Cas13a based circulating nucleic acid detection In 2017, the SHERLOCK system emerged as a pioneering Cas13a-driven approach. By coupling RPA with T7 transcription, SHERLOCK achieved attomolar sensitivity and 0.1% variant allele fraction (VAF) specificity for detecting EGFR and BRAF mutations in ctDNA [9]. Subsequent refinements in SHERLOCK v2 introduced Csm6, a type IIIA Cas protein, which amplifies the detection signal by 3.5-fold. This enhancement relies on Csm6 activation by the Cas13a-mediated trans-cleavage’s poly-A RNA fragments, leading to secondary reporter cleavage and enhancing fluorescence signals [15]. Recent Cas13a-based platforms emphasize clinical translation. The HiCASE (High-sensitivity PCR-Cas13a with Specific Restriction Enzyme detection) platform combines PCR with sequence-specific restriction enzymes to preferentially digest wildtype alleles, enriching mutant DNA for Cas13a analysis. In a cohort of 120 NSCLC patients, HiCASE detected EGFR mutations with 88.1% sensitivity and 100% specificity, outperforming droplet digital PCR (ddPCR) and amplification-refractory mutation system (ARMS) assays [16]. It is noteworthy that a Cas13a based platform called SCOPE (Self-amplified and CRISPR-aided Operation to Profile EVs) platform targets extracellular vesicle (EV) mRNA mutations by integrating Cas13a with T7 transcription. A self-amplifying RNA–DNA hybrid reporter releases fluorescent RNA fragments upon target recognition and unblocks DNA template for T7 transcription, initiating cascade transcription and CRISPR-Cas reaction cycles. This system attains sub-attomolar sensitivity for KRAS, BRAF, EGFR, and IDH1 mutations in colorectal cancer patient plasma EVs, enabling single-nucleotide resolution [107]. Cas12a based circulating nucleic acid detection Cas12a’s trans-nuclease capability has been harnessed for rapid, amplification-free ctDNA detection. A novel approach utilizes gold nanoparticles functionalized with a fluorescent reporter (FAM) and quencher (BHQ1) linked via a 7 nm dsDNA spacer. Cas12a activation by target DNA triggers cleavage of the DNA linker, displacing FAM from the nanoparticle surface and restoring fluorescence. This system achieves 0.34 fM sensitivity within 30 min, circumventing the need for pre-amplification [122]. Electrochemical biosensors further advance sensitivity by integrating nanomaterials. For instance, methylene blue (MB)-modified ssDNA encapsulating ferrocene (Fc) within UiO-66-NH2 frameworks enables dual-signal readouts. Cas12a-mediated cleavage of ssDNA releases Fc, altering MB and Fc redox currents proportionally to ctDNA concentration [123]. Another study presented a CRISPR-Cas12a-based biosensor for sensitive BRCA-1 cfDNA detection using DFM imaging. AuNPs (50 nm) were immobilized on a coverslip and modified with dsDNA, enabling AuNPs2 (20 nm) binding in the absence of BRCA-1, producing yellow/red scattering under DFM. Upon BRCA-1 presence, CRISPR-Cas12a cleaves unhybridized ssDNA, preventing AuNPs2 binding, resulting in green scattering. This biosensor realized cfDNA detection with femtomolar sensitivity without requiring nucleic acid amplification [124]. PRC-Cas, a PAM-independent, crRNA-optimized CRISPR/Cas12a assay for accurate ctDNA detection in NSCLC. By introducing PAM sequences via RPA or using suboptimal PAMs, PRC-Cas ensures broad applicability while minimizing false positives with crRNA mismatches. It successfully detected EGFR and KRAS mutations, demonstrated feasibility with clinical samples, and offered comparable sensitivity with faster results than qPCR, making it a promising tool for routine ctDNA mutation detection [105]. Cas9 based circulating nucleic acid detection Catalytically inactive Cas9 (dCas9) has been repurposed for ctDNA enrichment. Magnetic separation using His-tagged dCas9 and sgRNA enables selective capture of mutant alleles in cfDNA from NSCLC patients, enhancing downstream qPCR sensitivity [64]. Similarly, detection of ctDNA mutations has been reported using dCas9 proteins–sgRNA modified graphene oxide screen-printed electrodes, which induce electrochemical impedance changes upon complementary binding between the target ctDNA and sgRNA, enabling readout via electrochemical impedance spectroscopy [125]. Another electrochemical CRISPR-dCas9 biosensor demonstrated high sensitivity (2.86 fM) and 0.001% VAF selectivity for single-base mutant ctDNA detection. The assay used PCR-generated azide-modified ctDNA, which was unzipped by sgRNA-dCas9, allowing a biotin-labeled ssDNA reporter to hybridize with the exposed strand. The complex then bound to a gold electrode via click chemistry, inducing ionic current changes for electrochemical readout [126]. microRNA biomarker detection: advancing early detection and tumor classification MicroRNAs (miRNAs) are short non-coding RNAs that pose challenges for conventional PCR and sequencing due to their limited length. Recent advances in CRISPR diagnostics have revolutionized miRNA detection, offering rapid, sensitive, and specific diagnostic tools. Yan et al. introduced EXTRA-CRISPR, a one-pot isothermal assay that integrates rolling circle amplification (RCA) with the dual cleavage activity of CRISPR-Cas12a. In this system, cis-cleavage of Cas12a fragments RCA products to enable exponential amplification, while trans-cleavage generates fluorescent signals for readout. Achieving single-femtomolar (fM) sensitivity and single-nucleotide specificity within 1–2 h, EXTRA-CRISPR effectively detected extracellular vesicle (EV)-derived miRNAs (e.g., miR-21, miR-196a) in pancreatic cancer patient plasma, with results correlating with RT-qPCR [17]. Chen et al. engineered a split CRISPR-Cas12a system by dividing the canonical crRNA into two components: a scaffold RNA (structural support) and a spacer RNA (target recognition). Upon binding to the target miRNA, the spacer RNA activates Cas12a, initiating cleavage of single-stranded DNA (ssDNA) probes. This design enhances specificity by distinguishing mature miRNAs from precursors and detecting single-nucleotide polymorphisms (SNPs) with 100% sensitivity and 100% specificity for plasma samples obtained from seven individuals diagnosed with cervical cancer and three healthy individuals [18]. Recent studies have expanded the CRISPR toolbox by optimizing Cas12 variants. For instance, the trans-nuclease activity of Cas12j variants was repurposed for miRNA detection in clinical plasma samples from lung cancer patients, demonstrating versatility in cancer diagnostics [127]. Shen et al. designed a dumbbell probe-initiated multi-RCA-assisted CRISPR/Cas12a (DBmRCA) assay for detecting lung cancer-associated miRNAs (e.g., miR-200a, miR-126). A ligation-free dumbbell probe binds the target miRNA, undergoes structural rearrangement to expose primer-binding sites, and triggers multi-RCA. The resulting long ssDNA activates Cas12a for signal amplification, achieving a limit of detection (LOD) of 0.1 fM within 30 min for clinical lung cancer tissue specimens [128]. To eliminate amplification bias, Zhao et al. devised the Fragment Complementary Activation Strategy (FCAS) using Cas12a. By replacing crRNA-distal ssDNA activators with target miRNA sequences, FCAS activates Cas12a’s trans-cleavage without reverse transcription. This amplification-free method detected glioma-associated miRNA-10b in serum at 5.53 fM sensitivity [129]. A separate one-pot assay achieved unprecedented attomolar (aM) sensitivity (3.43 aM) for breast cancer biomarker miRNA-21 within 40 min. Here, miRNA-21 bridges two DNA probes for ligation, generating a template for RPA and subsequent Cas12a activation [130]. Innovative signal amplification strategies further enhance sensitivity. A 3D-DNA walker-CRISPR/Cas12a cascade system was developed for miRNA-141 detection, exploiting toehold-mediated DNA displacement and Cas12a-mediated cleavage. This method achieved an LOD of 0.14 fM and a linear range of 0.5–10,000 fM [19]. Chen et al. improved mismatch discrimination by employing truncated crRNA. Combining a PAM (protospacer adjacent motif)-containing stem-loop reverse transcription module, RPA, and Cas12a with short crRNA, this platform attained single-digit attomolar sensitivity and SNP specificity [131]. Beyond Cas12a, Cas13a-based systems have also been employed for miRNA detection. Hong et al. encapsulated CRISPR-Cas13a sensors in liposomes, enabling miRNA detection within intact extracellular vesicles (EVs) via liposome-EV fusion. This approach eliminated RNA extraction and pre-amplification while quantifying miRNA-positive EV counts [132]. A PddCas13a system coupled with digital droplet technology detected circular RNA (circRNA) and miRNA at 10 aM sensitivity, even in complex biological matrices such as clinical samples from CRC patients and healthy people, using chemically stabilized crRNAs [133]. Further integrating dual CRISPR systems, ddSEE (digital dual CRISPR-Cas-powered Single EV Evaluation) simultaneously profiled EV surface proteins (via Cas12a and antibody-DNA conjugates) and intravesicular miRNA (via Cas13a) within single EVs. Validated in breast cancer diagnostics, ddSEE achieved 92% accuracy in distinguishing patients from healthy donors [134]. Non-nucleic acid biomarkers detection: expanding the scope of CRISPR diagnostics While CRISPR diagnostics have demonstrated exceptional sensitivity and specificity in the direct detection of nucleic acids, they have expanded into the indirect identification of non-nucleic acid tumor biomarkers. This advancement is ensured by coupling synergistic approaches such as methylation-sensitive restriction enzymes, aptamers, DNAzymes and allosteric transcription factors (aTFs), enabling the translation of epigenetic, proteomic, and metabolic signals into nucleic acid sequences amenable to CRISPR-mediated recognition and amplification. Detection of epigenetic aberrations Cancer epigenetic aberrations encompass reversible, heritable changes in gene expression that drive oncogenesis without altering the DNA sequence. These include dysregulated DNA methylation, histone modifications, and chromatin remodeling, which silence tumor suppressors or activate oncogenes [135–137]. Detection of such aberrations holds significant potential for early cancer diagnosis. Among epigenetic alterations, site-specific DNA methylation is a key focus. CRISPR diagnostic platforms often employ bisulfite conversion or methylation-sensitive restriction enzymes (MSREs) to distinguish methylated DNA. For example, Xu et al. developed MeCRISPR, integrating MSREs with recombinase polymerase amplification (RPA) and CRISPR-Cas12a for rapid, ultrasensitive detection of methylated SEPT9, a cervical cancer biomarker. This method achieved single-copy/μL sensitivity and 0.01% specificity against background genomic DNA in clinical samples including Fifty-three cases of exfoliated cervical cells(CEC) samples from 27 patients with cervical cancer and 26 patients with non-cervical cancer, demonstrating 100% diagnostic sensitivity and 92.3% specificity [138]. However, such indirect approaches require converting methylation signals into CRISPR-recognizable sequences, resulting in detection limits above femtomolar levels, which may limit clinical utility. Recent innovations, such as Li et al.’s CRISPR-Cas12a platform using oligonucleotide-nanoparticle reporters, improved sensitivity to attomolar (aM) levels within 40–60 min in 4 tissue DNA samples from CRC patients and 16 healthy human buffy coat DNA samples [139]. Notably, Giesselmann et al. introduced STRique, a CRISPR-Cas9/12a-enhanced nanopore sequencing strategy for single-molecule methylation analysis. Target DNA was dephosphorylated, followed by Cas9/12a-mediated cleavage at loci like C9orf72 and FMR1 to generate 4-nt overhangs. Blunt-end repair and adapter ligation enabled direct methylation readouts via current signals during nanopore sequencing, bypassing amplification [20]. This method highlights CRISPR’s potential in high-resolution epigenetic profiling. Beyond DNA methylation, DNA methyltransferases (DNMTs), enzymes critical for methylation, are actionable biomarkers. Chen et al. designed a CRISPR-Cas12a biosensor to detect Dam methyltransferase activity. In the presence of Dam and its cofactor SAM, a 5′-GATC-3′ substrate is methylated and cleaved by DpnI, producing 3′-OH termini. Terminal deoxynucleotidyl transferase (TdT) extends these ends with poly-T tails, activating Cas12a’s trans-cleavage activity for signal amplification. This achieved a detection limit of 1.26 × 10–3 U/mL [140]. A similar approach was reported for broad-spectrum DNMT detection [141]. Protein biomarker detection Cancer-related protein biomarkers, characterized by their presence, absence, or dysregulated expression in tissues or biofluids, serve as critical indicators of tumor development, progression, and therapeutic response. These biomarkers, secreted by tumors or generated as part of the host’s reaction to malignancy, are indispensable for early diagnosis, prognosis, and treatment monitoring. While conventional methods such as immunohistochemistry (IHC) and enzyme-linked immunosorbent assays (ELISA) remain widely used, CRISPR-Cas systems have emerged as innovative tools for protein biomarker detection, offering advantages in cost-effectiveness, speed, and sensitivity. A notable advancement is the CRISPR/Cas13a-linked immunosorbent assay (CLISA), which enhances traditional ELISA by replacing its enzymatic reporter with a T7 promoter-linked biotinylated double-stranded DNA (dsDNA). Upon antigen binding, T7 RNA polymerase transcribes the dsDNA into RNA, activating the collateral RNase activity of Cas13a. This approach achieved detection limits of 45.81 fg/mL for interleukin-6 (IL-6) and 32.27 fg/mL for vascular endothelial growth factor (VEGF), representing a > 100-fold sensitivity improvement over conventional ELISA [21]. CRISPR-Cas systems have also been integrated with functional DNA elements, such as aptamers and DNAzymes, to convert protein recognition into nucleic acid signals. For instance, Cas12a-based biosensors targeting alpha-fetoprotein (AFP) and prostate-specific antigen (PSA) exploit high-affinity aptamers, translating protein binding into detectable DNA sequences which managed to detect targets in serum samples of liver cancer patients [142–144]. Further expanding this paradigm, Liu et al. engineered a SUMO-tagged Cas13a variant whose activity is inhibited by blocking crRNA docking. Protease-mediated cleavage of the SUMO tag restores Cas13a function, enabling detection of proteases like Ulp1 with a limit of detection (LOD) of 48.8 pg/μL [145]. Telomerase activity, a hallmark of cancer, has been quantified using CRISPR-Cas12a. Telomerase extends the TS primer with (TTAGGG)n repeats, which are recognized by Cas12a via complementary crRNA. Integration with droplet digital PCR (ddPCR) enables absolute quantification by counting fluorescence-positive droplets, achieving high precision in telomerase activity measurement [146]. Despite these advantages, it is important to contextualize CRISPR-based protein detection within the landscape of established clinical technologies. Automated chemiluminescence immunoassays, widely used in clinical laboratories, offer high throughput, standardized workflows, and robust reproducibility, making them the current gold standard for routine protein biomarker quantification. Similarly, mass spectrometry-based proteomics provides unparalleled specificity and multiplexing capability, enabling simultaneous quantification of numerous protein targets with high accuracy. In comparison, CRISPR-based assays currently demonstrate superior analytical sensitivity and flexible programmability but may face limitations in throughput, large-scale multiplexing, and clinical standardization. Additionally, while CRISPR platforms can reduce reagent costs and enable point-of-care applications, their integration into automated, high-throughput clinical systems remains an ongoing challenge. Small molecule and metabolite biomarkers detection Emerging evidence underscores the critical role of low-molecular-weight metabolites, including sugars, lipids, amino acids, and organic acids, as dynamic indicators of cancer-associated metabolic reprogramming. These biomolecules, detectable in biofluids such as blood, urine, and saliva, mirror systemic pathophysiological adaptations to malignancy, particularly dysregulation in hallmark pathways like the Warburg effect and glutaminolysis that fuel tumor proliferation, invasion, and immune suppression [147]. Small-molecule biomarkers offer unique advantages in oncology by enabling real-time monitoring of metabolic plasticity during cancer progression and therapeutic intervention. NAD⁺ (nicotinamide adenine dinucleotide) and ATP (adenosine triphosphate) exemplify pivotal metabolites in cancer biology, serving as dual biomarkers of tumor bioenergetics and redox homeostasis. Elevated ATP concentrations correlate with the heightened energy demands of proliferative cancer cells, while NAD⁺ dysregulation reflects compromised redox balance and aberrant DNA repair mechanisms in malignancies. Recent advances in enzymatic biosensing have enabled ultrasensitive detection of these metabolites through innovative CRISPR-Cas integration. A representative biosensor [148] employs NAD+/ATP-dependent DNA ligase coupled with CRISPR/Cas12a trans-nuclease activity. In this system, target metabolites catalyze ligase-mediated repair of a gapped double-stranded DNA (dsDNA) substrate, generating intact dsDNA that activates Cas12a. This cascade triggers fluorescent signal amplification via non-specific single-stranded DNA cleavage, achieving remarkable detection limits of 10 pM for NAD+ and 50 pM for ATP. Parallel strategies exploit aptamer-CRISPR hybrids [23, 149, 150] and allosteric DNAzymes [22] for ATP sensing. The latter platform utilizes an ATP-binding aptamer-DNAzyme chimera that undergoes target-induced self-cleavage to release primer sequences, initiating rolling circle amplification (RCA) and subsequent CRISPR-Cas12a activation, achieving quantification within the 10–250 μM range with high specificity. Intriguingly, A method for ATP detection using the CRISPR-Cas13a system was developed based on aptamer-derived crRNAs (ap-crRNAs), enabling the Cas13a/ap-crRNA binary ribonucleoprotein (RNP) to respond to ATP in a concentration-dependent manner with high specificity. The assay achieved a detection limit as low as 1 mmol L⁻1 and a limit of detection (LOD) of 0.88 mmol L⁻1 [151]. Allosteric transcription factors (aTFs) have emerged as modular biosensing components due to their ligand-responsive conformational switching. These molecular switches regulate DNA binding affinity through interactions with small-molecule effectors, enabling programmable integration with CRISPR diagnostics. The CaT-SMelor platform [24] exemplifies this paradigm by immobilizing aTFs on microcrystalline cellulose matrices. Target-induced aTF conformational changes release PAM-containing dsDNA activators, which engage Cas12a to initiate trans-cleavage of fluorescent reporters. This approach demonstrates broad applicability for clinical biomarkers in clinical human serum samples, including uric acid and p-hydroxybenzoic acid detection, through customizable aTF-DNA interactions. Towards next generation CRISPR diagnostics Recent advancements in CRISPR-based diagnostics attempt to overcome critical limitations through innovations across four key aspects: PAM-free detection (Fig. 5a), ultra-sensitive/specificity (Fig. 5b), quantitativeness (Fig. 5c) and point-of-care testing (Fig. 5d). These multi-faceted innovations collectively advance CRISPR diagnostics toward universal nucleic acid detection with laboratory-grade performance in field-deployable formats. Fig. 5Towards next-generation CRISPR diagnostics. a PAM-free detection. Implementation of natural Cas orthologs (e.g., ScCas9 with NNG PAM, LbCas12a with suboptimal VTTV PAM) and engineered variants (e.g., SpCas9-NG, AsCas12a with TTCC and TCCC PAM), complemented by structural DNA modifications (helper strand-mediated sticky ends, RPA-generated ssDNA overhangs) to transform dsDNA to ssDNA for PAM independence. b Ultra-sensitivity and ultra-specificity. Ultra-sensitivity is achieved through coupling with nucleic acid amplification techniques, hyperactive Cas mutants (LwaCas13a-R474A), split-crRNA enabling cascade amplification, and T7 polymerase-coupled transcription-amplification circuits. Ultra-specificity integrates optimal mismatches introduction, modified crRNAs(2′-OMe modified), target modification and mismatch-intolerant variants (AsCas12a4m) engineering. c Quantitativeness. Optimizing nucleic acid amplification and CRISPR-Cas reaction conditions, coupling with digital droplet and microfluidic devices can correlate target concentration to end-point signal intensity linearly. d Towards POCT. Equipped with ultra-sensitive platform, integrated microfluidic device, POCT reader and wearable devices, CRISPR diagnostics evolved towards achieving POCT for field-deployable use. Towards next-generation CRISPR diagnostics. a PAM-free detection. Implementation of natural Cas orthologs (e.g., ScCas9 with NNG PAM, LbCas12a with suboptimal VTTV PAM) and engineered variants (e.g., SpCas9-NG, AsCas12a with TTCC and TCCC PAM), complemented by structural DNA modifications (helper strand-mediated sticky ends, RPA-generated ssDNA overhangs) to transform dsDNA to ssDNA for PAM independence. b Ultra-sensitivity and ultra-specificity. Ultra-sensitivity is achieved through coupling with nucleic acid amplification techniques, hyperactive Cas mutants (LwaCas13a-R474A), split-crRNA enabling cascade amplification, and T7 polymerase-coupled transcription-amplification circuits. Ultra-specificity integrates optimal mismatches introduction, modified crRNAs(2′-OMe modified), target modification and mismatch-intolerant variants (AsCas12a4m) engineering. c Quantitativeness. Optimizing nucleic acid amplification and CRISPR-Cas reaction conditions, coupling with digital droplet and microfluidic devices can correlate target concentration to end-point signal intensity linearly. d Towards POCT. Equipped with ultra-sensitive platform, integrated microfluidic device, POCT reader and wearable devices, CRISPR diagnostics evolved towards achieving POCT for field-deployable use. “PAM free” The protospacer adjacent motif (PAM), a short conserved nucleotide sequence adjacent to the protospacer, was first identified by Mojica et al. in 2005 as a critical determinant for target selection and spacer orientation in prokaryotic CRISPR-Cas defense systems [152]. PAM recognition by Cas effector proteins is a prerequisite for target cleavage, serving as a safeguard to differentiate self from non-self DNA in prokaryotes. However, in diagnostic applications, the PAM requirement imposes significant constraints on detecting nucleic acid targets lacking compatible PAM sequences. Consequently, the discovery of "PAM-free" nucleases or methodologies represents a pivotal advancement for CRISPR-based diagnostics. PAM-free CRISPR-Cas9 system Natural Cas9 variants exhibit diverse PAM preferences, expanding the range of detectable sequences. For instance, certain Cas9 orthologs recognize C-rich (NVNDCCY; V = A/C/G), T-rich (NR(A > G)TTTT), or A-rich (NNAAAR(G > A)) PAMs, while Streptococcus canis Cas9 (ScCas9) demonstrates unprecedented flexibility with an NNG motif [153, 154]. Collectively, these variants cover approximately 65% of possible nucleotide combinations, significantly broadening targetable sequences [155]. Engineered variants further enhance PAM versatility: SpCas9-NG, a Streptococcus pyogenes Cas9 derivative with seven mutations in its wedge and PAM-interacting domains, recognizes NG PAMs, enabling detection of previously inaccessible targets [156]. Furthermore, in light of the recent discovery of Cas9’s trans-nuclease activity [46], CRISPR-Cas9-based diagnostics hold significant potential for the development of PAM-free detection platforms. PAM-free CRISPR-Cas12 system In contrast to Cas9, most natural Cas12a orthologs exhibit T-rich PAM preferences (e.g., TTN). However, Cas12a’s robust trans-cleavage activity, which rapidly degrades non-specific single-stranded DNA (ssDNA), positions it as an ideal signal amplifier for diagnostics [5, 157, 158]. Recent mechanistic insights reveal that Cas12a bypasses PAM dependence when targeting unwound DNA, as PAM recognition becomes dispensable post-DNA unwinding during R-loop formation [31]. This principle has inspired innovative strategies to circumvent PAM constraints. For double-stranded DNA (dsDNA) targets, converting dsDNA to ssDNA or introducing single-stranded overhangs eliminates PAM dependency. Ding et al. demonstrated PAM-free detection of SARS-CoV-2 by coupling recombinase polymerase amplification (RPA) with dual crRNAs targeting exposed single-stranded regions generated during amplification, achieving enhanced sensitivity by minimizing cis-cleavage interference [10]. Similarly, Zhang et al. showed that sticky-ended dsDNA, formed by annealing PCR products with complementary “helper strands”, activates Cas12a without PAM recognition [159]. Toehold-mediated strand displacement offers another approach: Zhu et al. engineered RPA primers with uracil substitutions, enabling enzymatic generation of single-stranded toeholds that activate Cas12a via strand displacement [160]. Protein engineering further expands Cas12a’s PAM compatibility. Tóth et al. identified key mutations in Acidaminococcus Cas12a (AsCas12a; e.g., S542R, K548V, N552R, K607R) that relax PAM specificity, enabling recognition of non-canonical motifs like TTCC and TCCC [161]. Beyond Cas12a, recent work on tracrRNA-dependent Cas12 subtypes (e.g., Cas12b, Cas12e, Cas12f) revealed PAM-free RNA detection by reprogramming tracrRNAs to convert target RNA into guide RNAs [162]. Similarly, the Functionalized Amplification CRISPR Tracing (FACT) method amplifies the target sequence using crRNA sequence-containing primers, generating dsDNA containing mixed sequences. In vitro transcription then produces spacer-containing crRNA, which complexes with Cas12a to interact with preset PAM-containing dsDNA, triggering trans-nuclease activation for detection [163]. PAM-free CRISPR-Cas13 system Cas13a, an RNA-guided RNase, initially demonstrated RNA virus interference in prokaryotes through recognition of protospacer flanking sites (PFS), analogous to DNA-targeting PAMs [6]. However, PFS dependence varies across orthologs; for instance, Leptotrichia wadei Cas13a (LwaCas13a) and Prevotella sp. Cas13b (PspCas13b) exhibit minimal PFS requirements, enabling PAM-flexible RNA detection [164, 165]. Cas13-based platforms like SHERLOCK have been successfully deployed for SARS-CoV-2 and cancer mutation detection, leveraging Cas13’s collateral cleavage of reporter RNAs upon target recognition. While Cas13’s intrinsic flexibility reduces PAM-related limitations, its off-target activity poses challenges for specificity. Future advancements in single-nucleotide discrimination, such as engineered high-fidelity variants or mismatch-sensitive guide designs, could unlock its full potential for precision diagnostics. Collectively, the evolution of CRISPR-Cas systems for diagnostics has centered on overcoming PAM/PFS restrictions through protein engineering, mechanistic insights, and innovative assay designs. Cas9 variants with broadened PAM recognition, Cas12a activation via structural DNA modifications, and Cas13’s inherent PFS flexibility collectively demonstrate progress toward universal nucleic acid detection. However, balancing sensitivity, specificity, and ease-of-use remains critical for translating these technologies into robust diagnostic platforms. Continued exploration of Cas enzyme diversity and rational engineering will further advance CRISPR-based tools toward PAM-free, high-resolution molecular detection. Ultra-sensitivity The discovery of trans-nuclease activity in Cas proteins, initially unveiled in Cas13a, marked a pivotal advancement in nucleic acid detection. Stoichiometric titration experiments revealed that LbCas12a exhibits single-turnover cis-cleavage but multi-turnover trans-cleavage, a property also identified in type III (Csm/Cmr) and type VI (Cas13a) effectors [5, 6, 166]. These findings positioned CRISPR-Cas systems as powerful tools for ultrasensitive diagnostics, leveraging their catalytic amplification capabilities. The sensitivity of CRISPR-based detection is governed by the enzymatic kinetics of trans-cleavage, quantified via Michaelis–Menten parameters (Km, kcat). Initial studies reported LbCas12a’s kcat as ~ 17 s−1 (dsDNA-activated) and ~ 3 s−1 (ssDNA-activated), with catalytic efficiencies (kcat/Km) of 1.7 × 107 s−1 M−1 and 5.0 × 106 s−1 M−1, respectively, suggesting dsDNA enhances trans-nuclease activity [5]. However, discrepancies emerged when subsequent models revised LbCas12a’s kcat from 1250 to 17 s−1, underscoring the need for standardized kinetic assays [167]. Despite intrinsic picomolar-level sensitivity, unamplified CRISPR systems remain insufficient for clinical detection of low-abundance targets (e.g., circulating tumor DNA), necessitating pre-amplification or innovative engineering [9, 167]. Cas Enzyme engineering has yielded hyperactive variants, such as a LwaCas13a mutant incorporating an RNA-binding motif near its HEPN domain, enabling attomolar SARS-CoV-2 detection via electrochemical readouts without pre-amplification [168]. Structural refinements to crRNA significantly enhance signal output. A 7-mer dsDNA extension at the crRNA 3′-end amplified fluorescence signals by 3.5-fold [169]. Recently, a study conducted by Chen et al. discovered that coupled with split crRNAs that divided canonical crRNA into a scaffold RNA and a spacer RNA, Cas12a could be directly harnessed for RNA substrate detection with femtomolar level sensitivity without reverse transcription and pre-amplification, and also presented higher sensitivity for dsDNA or miRNA point mutation discrimination [170]. Tolerance for non-canonical crRNA extensions (e.g., in stem-loop regions) further permits crRNA optimization to enhance its stability in biofluids, which is critical for liquid biopsy applications [87]. Signal amplification cascades design by Integrating CRISPR with nucleic acid amplification mechanisms, such as T7 polymerase-driven transcription, has unlocked sub-attomolar sensitivity. In this cascade, a hybrid RNA–DNA reporter, cleaved by Cas13a to unblock the target template which transcribed into target RNA by T7 polymerase in in vitro, detected tumor-derived extracellular vesicle mutations in clinical samples, bypassing pre-amplification [107]. Ultra-specificity Current CRISPR diagnostics achieve single-nucleotide discrimination in specific contexts by incorporating mismatches into crRNA designs. However, these strategies remain context-dependent, limiting their applicability for detecting widespread single-nucleotide polymorphisms (SNPs), especially in cancer. Developing universally robust, ultra-specific CRISPR platforms is critical for advancing precision diagnostics. CRISPR specificity hinges on two sequential processes: (1) target recognition and binding (E + S ↔ ES), governed by reversible equilibrium kinetics, and (2) irreversible trans-nuclease activation (ES → E + P), described by Michaelis–Menten kinetics. Here, specificity is determined by the forward (kforward) and reverse (kreverse) binding rates, alongside the catalytic turnover rate (kcat). To discriminate SNPs, existing approaches introduce mismatches in crRNA-target hybrids to destabilize binding (increasing kreverse) and suppress trans-cleavage activity (reducing kcat), amplifying signal differences between wildtype and mutant targets [15, 171, 172]. Yet, this strategy is constrained to specific genomic regions. For example, LbCas12a tolerates mismatches outside the PAM and seed regions (+ 1 to + 5 positions), while LbuCas13a exhibits sensitivity to mismatches only within specific crRNA sites (e.g., positions 5–16) [5, 82]. Such limitations hinder broad SNP detection. Directed evolution and rational mutagenesis of Cas enzyme have yielded hyper-discriminative Cas variants. AsCas12a4m, a quadruple mutant (S186A/R301A/T315A/Q1014A), demonstrates zero tolerance for single mismatches across positions 1–19, contrasting wildtype AsCas12a, which detects mismatches only at positions 2–7 [173]. Similarly, LbuCas13aN378A and LbuCas13aR973A variants enhance mismatch discrimination at low RNA target concentrations, particularly at positions 7 and 19 [82]. These modifications expand targetable regions beyond canonical hotspots. crRNA engineering offers a versatile approach to improve specificity. For LbuCas13a, shorter crRNAs (16–20 nt) exhibit heightened mismatch intolerance compared to longer variants (28 nt), likely due to reduced non-specific interactions [82]. In Cas12a systems, truncating crRNA to 17 nt and introducing a secondary mismatch at position 14 enhances SNP discrimination without compromising sensitivity [174]. Structural modifications, such as spacer-region hairpins in sgRNA, elevate SpCas9 specificity by orders of magnitude by sterically hindering off-target binding [175]. Chemical modifications, including 3’-end 2’-O-methylation of crRNA, further reduce off-target affinity in Cas12a systems [176]. Innovations in substrate engineering exploit Cas12a’s affinity for sticky-ended dsDNA, which exhibits heightened sensitivity to single-base mismatches. Zhang et al. leveraged this property to detect low-abundance mutations (0.005–0.05% allele frequency) in clinical samples [159]. Reporter systems have also been refined: Hu et al. developed a triple-mismatch assay combining crRNA-target mismatches and reporter-target mismatches, achieving a detection limit of 0.0001% for SNP identification [106]. The interplay between biophysical interactions and reaction kinetics underpins specificity enhancement. For instance, mismatches in crRNA alter binding energy landscapes, while kcat modulation fine-tunes enzymatic activity post-binding. Advances in single-molecule imaging and computational modeling are unraveling these dynamics, informing rational design principles [35]. Despite progress, challenges persist. Most engineered systems remain tailored to specific enzymes or targets, lacking universal applicability. Integrating multi-omics data, machine learning-guided crRNA design, and high-throughput screening of Cas variants could democratize ultra-specific diagnostics. Furthermore, standardized metrics for specificity validation—akin to qPCR’s MIQE guidelines—are urgently needed to ensure reproducibility. In addition, while protein and crRNA engineering have unlocked unprecedented specificity, a deeper understanding of CRISPR enzymology—from structural biophysics to kinetic profiling—will drive the next leap. Quantitativeness While CRISPR-based diagnostics achieve attomolar sensitivity comparable to quantitative PCR (qPCR), their quantitative capabilities remain constrained by narrow dynamic ranges. qPCR, the gold standard for absolute quantification, offers a broad dynamic range (typically spanning 6–8 orders of magnitude) and adheres to MIQE guidelines for reproducibility, whereas most CRISPR assays rely on semi-quantitative endpoint readouts such as fluorescence intensity or lateral flow strips. These methods exhibit variability influenced by Cas enzyme kinetics, sample matrices, and inconsistent amplification efficiency [177]. In nucleic acid pre-amplification-coupled CRISPR diagnostics, optimization of amplification and CRISPR-Cas reaction conditions has proven helpful for enhancing quantification capability. SHERLOCKv2 demonstrated quantification of nucleic acids at 2 attomolar by modulating recombinase polymerase amplification (RPA) primer concentrations (120 nM) [15]. Similarly, Yao et al. developed a one-pot isothermal Cas12a-RPA assay (OICRQ), correlating time-to-inflection point (POI) of real-time fluorescence with target DNA concentrations (101–107 copies/reaction) through optimized primer (320 nM) or Cas12a/crRNA (100 nM) concentrations [178]. An approach based on CRISPR-Cas12b-assisted loop-mediated isothermal amplification (LAMP) enabled quantification of hepatitis B virus (HBV) DNA at 25 copies/mL in clinical samples by refining buffer composition, AapCas12b-gRNA levels (0.5 μM), and temperature (60–64 °C) [179]. Digital CRISPR systems are transforming nucleic acid quantification by directly addressing the limitations inherent in traditional amplification-based techniques. Conventional methods like PCR depend on standard curves and involve thermal cycling, which can extend assay times and compromise sensitivity, particularly for low-abundance targets. In contrast, recent research has demonstrated that by partitioning the reaction mixture into millions of micro-reactions, digital CRISPR platforms can achieve absolute quantification through Poisson statistics, thereby eliminating the need for standard curves. For instance, the opn-SATORI system, as reported by Shinoda et al., employs a microchamber array with picoliter volumes to create over 108 independent partitions, achieving a limit of detection (LOD) as low as 6.5 attomolar in under 9 min [180]. This high level of sensitivity is made possible because each micro-reaction functions as an isolated environment, significantly boosting the effective concentration of target molecules and minimizing the impact of false positives. Similarly, studies by Son et al. have further refined this approach by incorporating multiple CRISPR RNAs (crRNAs) into the assay. Their digital CRISPR platform harnesses the collateral cleavage activity of Cas13, and by targeting several regions simultaneously, it achieved a LOD of 1 copy/uL within a 15-min testing window [181]. Such innovations not only enhance the specificity of target detection but also dramatically reduce the turnaround time compared to traditional methods. A recent study further unveiled that water-in-oil-in-water (W/O/W) double emulsion (DE) droplets outperform traditional single emulsion (SE) systems, offering enhanced stability, reduced cross-contamination, and compatibility with high-throughput flow cytometry [182]. Additionally, paper-based microfluidics integrated with CRISPR-Cas12a were recently reported to enable visual quantification. Unlike conventional fluorophore–quencher systems, this probe comprises a hydrophobic Cy5 fluorophore head linked to a hydrophilic single-stranded DNA tail. When target nucleic acids are present, the CRISPR-Cas12a enzyme is activated and cleaves the probe’s hydrophilic tail, releasing the hydrophobic Cy5 head. This release alters the wettability of the reaction mixture, which, when applied to a paper-based microfluidic device, limits the diffusion distance of the fluorescent signal. The resulting change in fluorescence diffusion distance is directly correlated with the target concentration, enabling visual and quantitative detection [183]. POCT CRISPR diagnostics have emerged as transformative tools for point-of-care testing (POCT), exemplified by platforms such as SHERLOCK and DETECTR. These systems integrate isothermal amplification (e.g., RPA, LAMP) with CRISPR-Cas-mediated trans-cleavage to generate fluorescence, colorimetric, or electrochemical signals. When coupled with portable readouts such as lateral flow assays (LFAs), they enable equipment-free, user-friendly detection, ideal for resource-limited settings. Recent advancements focus on enhancing sensitivity, eliminating preprocessing steps, and improving portability. For instance, Huang et al. achieved femtomolar (fM) sensitivity in raw clinical samples using polydopamine nanospheres (PDANSs) as cyclic amplification nanoquenchers, bypassing nucleic acid amplification [184]. Similarly, Zhang et al. leveraged hairpin DNA substrates to develop an electrochemical biosensor with 30 pM sensitivity [185]. Innovations in hardware miniaturization—such as 3D-printed fluorescence detectors [186, 187] and microfluidic integration—further streamline workflows. Bruch et al. demonstrated a handheld device combining Cas13a with glucose oxidase (GOx) for H2O2-mediated electrochemical detection [188], while repurposed glucose meters enabled nucleic acid quantification via invertase-functionalized hydrogels or magnetic beads (MBs). When coupled with glucose meter, Liu et al. further developed polyinvertase-modified magnetic beads (MBs) to achieve “1:n” signal amplification [189] while Zhu et al. developed a solid-phase reporter labeled with invertase that effectively bridges CRISPR-Cas system-mediated target recognition with personal glucose meter readout, thereby facilitating HPV detection in a point-of-care-compatible format [190]. Colorimetric readouts prioritize visual interpretation, exemplified by LFAs and enzyme-mediated chromogenic reactions. SHERLOCKv2 and HOLMESv2 employ gold nanoparticles (AuNPs) or horseradish peroxidase (HRP) for smartphone-compatible color changes [15, 191]. Emerging distance-based systems, such as Shao et al.’s PtNP-driven oxygen generation platform, translate target concentrations into ink migration distances on microfluidic chips, offering quantitative readouts without instrumentation [192]. Despite progress, key challenges impede widespread POCT adoption. First, reliance on isothermal amplification introduces risks of aerosol contamination and false positives, necessitating amplification-free strategies [188, 193]. Second, portability–sensitivity trade-offs persist: fluorescence/electrochemical systems require handheld devices, while colorimetric methods remail susceptible to subjective interpretation [194, 195]. Third, reagent instability, particularly crRNA degradation under variable storage conditions, remains unresolved [196]. Fourth, multiplexing is hindered by nonspecific trans-cleavage activity of Cas nucleases [191, 192]. Finally, scalability and cost barriers limit the transition from proof-of-concept systems to commercial deployment. To fully realize the potential of CRISPR-based point-of-care testing (POCT), three key advancements are crucial. First, amplification-free detection methods—such as Xu et al.’s dual-enhancement electrochemical biosensor achieving femtomolar sensitivity [193]—can reduce both preprocessing steps and contamination risks. Second, integrated microfluidic platforms using disposable cartridges, exemplified by Li et al.’s HIV-1-detecting polymer chip [197], streamline workflows by consolidating extraction, optional amplification, and detection into a single device. Finally, smartphone-enabled quantification supported by cloud-based image analysis canstandardize colorimetric and distance-based outputs. This approach is demonstrated by Nguyen et al.’s mask-embedded lateral flow assay (LFA) [198] and Xiong et al.’s dual-gene test strip [191], highlighting how portable digital tools can further enhance CRISPR-POCT’s accessibility and utility. Addressing these challenges will require harmonizing engineering innovation with robust clinical validation to deliver scalable, affordable, and reliable CRISPR-POCT solutions. Conclusion CRISPR-Cas systems have redefined molecular diagnostics, offering unparalleled sensitivity, specificity, and versatility. From their inception as bacterial defense mechanisms to their current status as cutting-edge diagnostic tools, these systems have demonstrated transformative potential across infectious disease management, cancer diagnostics, and liquid biopsy. The COVID-19 pandemic underscored their utility in rapid, decentralized testing, with platforms like SHERLOCK achieving global deployment for emergency use. In oncology, CRISPR diagnostics address critical challenges in detecting low-abundance mutations, epigenetic alterations, and other non-nucleic acid biomarkers. Innovations such as hyperactive Cas variants, split crRNA designs, and amplification-free strategies enable precise identification of oncogenic drivers like EGFR and KRAS at clinically relevant VAFs. Liquid biopsy applications, particularly for ctDNA and EV-derived biomarkers, highlight CRISPR’s capacity for non-invasive, real-time monitoring of tumor dynamics. Although progress has been made, significant challenges persist. PAM/PFS dependencies, though mitigated by enzyme engineering, still limit universal targetability. Quantitative accuracy, while improved through digital partitioning, still lags behind qPCR. Furthermore, transitioning proof-of-concept assays into clinically validated tools requires rigorous standardization and scalability. In the future, interdisciplinary collaboration will be essential. By integrating CRISPR with microfluidics, nanomaterials, and AI-driven design, researchers can enhance portability and enable multiplex testing. Meanwhile, advances in amplification-free detection and the development of cold chain-independent reagents will further enable POCT and broaden the accessibility of CRISPR diagnostics. Combining CRISPR programmability with these emerging technologies positions it as a cornerstone of next-generation molecular diagnostics, bridging the gap between laboratory innovation and real-world clinical practice.